<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.22.4 -->
<!-- Round: 4 -->
<!-- Creation date: 2015-11-16T17:54:35Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:emis="http://emisphere.com/20150930" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="emis-20150930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE5372----1510-Q0007_STD_0_20060516_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_E83D7809-E371-49DE-9910-E4223A88D347_2_3">3.78</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE5372----1510-Q0007_STD_0_20140820_0" unitRef="iso4217_USD" decimals="INF" id="id_9160902_0A31FAF1-8745-4566-A409-490F78A328FF_1001_0">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20140820_0_1643325x1741680" unitRef="iso4217_USD" decimals="INF" id="id_9160902_0A31FAF1-8745-4566-A409-490F78A328FF_3001_2">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20141104_0_1643325x1741680" unitRef="iso4217_USD" decimals="INF" id="id_9160902_0A31FAF1-8745-4566-A409-490F78A328FF_3002_2">3000000</us-gaap:DebtInstrumentFaceAmount>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE5372----1510-Q0007_STD_0_20151116_0" unitRef="shares" decimals="INF" id="id_9160902_46C9DFF1-11EF-4B62-A749-FDE81E2D8BE5_2_5">60687478</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20150406_0_1643325x1741680" unitRef="iso4217_USD" decimals="INF" id="id_9160902_0A31FAF1-8745-4566-A409-490F78A328FF_3004_2">5000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20100608_0_1643325x1691094" unitRef="iso4217_USD" decimals="INF" id="id_9160902_EEFA6D13-0D51-471F-9178-8BF32753C5CE_1002_0">600000</us-gaap:DebtInstrumentFaceAmount>
  <emis:LineOfCreditFacilityAdditionalBorrowings contextRef="eol_PE5372----1510-Q0007_STD_0_20150701_0_1639304x1633605" unitRef="iso4217_USD" decimals="INF" id="id_9160902_0A31FAF1-8745-4566-A409-490F78A328FF_2005_3">2000000</emis:LineOfCreditFacilityAdditionalBorrowings>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20150701_0_1643325x1741680" unitRef="iso4217_USD" decimals="INF" id="id_9160902_F9EAE36F-D051-49F4-9D78-016149F87AE3_3006_3">2000000</us-gaap:DebtInstrumentFaceAmount>
  <emis:NetProceedsOfSecuredLoanAgreement contextRef="eol_PE5372----1510-Q0007_STD_0_20050926_0" unitRef="iso4217_USD" decimals="-5" id="id_9160902_E83D7809-E371-49DE-9910-E4223A88D347_1_0">12900000</emis:NetProceedsOfSecuredLoanAgreement>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1510-Q0007_STD_0_20050926_0_1643325x1691094" unitRef="pure" decimals="INF" id="id_9160902_E83D7809-E371-49DE-9910-E4223A88D347_2001_2">0.11</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20050926_0_1643325x1691094" unitRef="iso4217_USD" decimals="INF" id="id_9160902_E83D7809-E371-49DE-9910-E4223A88D347_2001_1">15000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20121017_0_1643325x1936828" unitRef="iso4217_USD" decimals="INF" id="id_9160902_51B24575-9186-41D6-93FB-01EE24397EA3_1001_0">1400000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1510-Q0007_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1002_24">3986000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:TreasuryStockShares contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_40">289732</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_34">400000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_31">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_36">60687478</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_6D82B853-4C1F-4E11-AE71-359077DB7669_1_1">2913766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_33">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:SharesIssued contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_6D82B853-4C1F-4E11-AE71-359077DB7669_2_0">9195376</us-gaap:SharesIssued>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_29">4000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="pure" decimals="INF" id="id_9160902_23E5D91D-D0C5-4717-A2C6-8175C4340284_2001_0">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_30">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_35">60977210</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_28">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0B126E14-958E-4CC3-B49C-BC41A2557FEB_1_1">148000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0B126E14-958E-4CC3-B49C-BC41A2557FEB_1_0">31000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_37">405750000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DueToRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_19">2201000</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0B126E14-958E-4CC3-B49C-BC41A2557FEB_1_3">253000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_16">427000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_41">-141985000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_1_12">41836000</us-gaap:DerivativeLiabilities>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_F65FE63F-019E-434B-9906-8AB918F94AC5_1_1">743000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_12">1672000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccruedVacationCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_F65FE63F-019E-434B-9906-8AB918F94AC5_1_2">70000</us-gaap:AccruedVacationCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_13">382000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_F65FE63F-019E-434B-9906-8AB918F94AC5_1_0">859000</us-gaap:AccountsPayableCurrent>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_18">58669000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_1001_5">31357000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_38">-544393000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_24">146509000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_42">4524000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="INF" id="id_9160902_723E5A9D-1E51-4457-B6B2-830671934A57_1_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_21">41616000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_32">610000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_25" />
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_1001_3">613000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_1_5">58669000</us-gaap:NotesPayable>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_17">13001000</us-gaap:LiabilitiesCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_27" />
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0B126E14-958E-4CC3-B49C-BC41A2557FEB_1_2">74000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:InventoryRawMaterials contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_848B7039-2C8C-4440-A013-75A544E27D8D_1001_0">560000</us-gaap:InventoryRawMaterials>
  <us-gaap:SecurityDeposit contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_8">24000</us-gaap:SecurityDeposit>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-5" id="id_9160902_CE6D1025-AB09-4084-A813-8B9815EA677A_3_1">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:Assets contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_9">4524000</us-gaap:Assets>
  <us-gaap:Cash contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-5" id="id_9160902_F488C0E5-0AFB-4491-8985-7530FF1F1680_1001_3">1400000</us-gaap:Cash>
  <us-gaap:InventoryNet contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_4">2054000</us-gaap:InventoryNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_3">305000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_7">15000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_1_4">9001000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DepositsAssetsCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8CC2229C-510A-4C71-9EE9-D4B28A839C3F_1_1">184000</us-gaap:DepositsAssetsCurrent>
  <us-gaap:TreasuryStockValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_39">3952000</us-gaap:TreasuryStockValue>
  <us-gaap:AssetsCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_6">4485000</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidInsurance contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8CC2229C-510A-4C71-9EE9-D4B28A839C3F_1_0">37000</us-gaap:PrepaidInsurance>
  <us-gaap:InventoryFinishedGoods contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_848B7039-2C8C-4440-A013-75A544E27D8D_1001_2">1494000</us-gaap:InventoryFinishedGoods>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_5">722000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_2">1404000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_1001_2">628000</us-gaap:PropertyPlantAndEquipmentGross>
  <emis:LiabilitiesRecordedForIndemnificationProvisions contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="INF" id="id_9160902_1AB59213-7EFE-4882-ACDF-5E638CE77CEA_1001_0">0</emis:LiabilitiesRecordedForIndemnificationProvisions>
  <emis:MinimumRequiredCashBalance contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="INF" id="id_9160902_F794039F-799D-4677-95F5-418C4FB01A8C_1001_0">10000000</emis:MinimumRequiredCashBalance>
  <emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_23">12000</emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent>
  <emis:PrepaidExpensesAndOtherCurrentAssets contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8CC2229C-510A-4C71-9EE9-D4B28A839C3F_1_2">501000</emis:PrepaidExpensesAndOtherCurrentAssets>
  <emis:MinimumRequiredCashBalanceUnderCondition contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="INF" id="id_9160902_F794039F-799D-4677-95F5-418C4FB01A8C_1001_1">15000000</emis:MinimumRequiredCashBalanceUnderCondition>
  <emis:DerivativeLiabilitiesRelatedPartyCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_15">10520000</emis:DerivativeLiabilitiesRelatedPartyCurrent>
  <emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_20">30889000</emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent>
  <emis:RoyaltyPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_1_22">121000</emis:RoyaltyPayable>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634505x1633425" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_2001_1">27000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634505x1638371" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_3001_0">601000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634760x1634767" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0EB85DFF-E467-4899-A6D0-292C58158313_2002_1">31357000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634760x1637150" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0EB85DFF-E467-4899-A6D0-292C58158313_2001_1">10479000</us-gaap:DerivativeLiabilities>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1637754" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_2001_0">0.56</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1637754" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1701830" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_1001_7">464000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732474" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_2001_0">0.56</us-gaap:SharePrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732474" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_2001_0">27180000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732474" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_2001_3">177000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732474" unitRef="iso4217_USD" decimals="-6" id="id_9160902_E5FF736E-174B-47C3-AD97-2E9F194E5033_1001_0">10000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732474" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_2001_1">1.25</emis:FairValueAssumptionConversionPrice>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_2001_0">0.56</us-gaap:SharePrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732774" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_3001_1">987000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732774" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_3001_2">50000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1733630" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_4001_3">1774000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1737996" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_2001_0">0.56</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1737996" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_2001_1">1.09</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1737996" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_5001_9">426000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1774308" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_6001_8">1432000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1783900" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_7001_4">468000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1802496" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_2001_0">0.56</us-gaap:SharePrice>
  <us-gaap:CommonStocksIncludingAdditionalPaidInCapital contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1802496" unitRef="iso4217_USD" decimals="-6" id="id_9160902_EB988641-BC7E-46DC-B7AB-0ED423EBFBCC_2001_1">10000000</us-gaap:CommonStocksIncludingAdditionalPaidInCapital>
  <emis:NumberOfWarrantsIssued contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1802496" unitRef="shares" decimals="INF" id="id_9160902_EB988641-BC7E-46DC-B7AB-0ED423EBFBCC_2001_0">865000</emis:NumberOfWarrantsIssued>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1802496" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1821050" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_8001_11">4757000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1830936" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_9001_10">378000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1860618" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_10001_5">1248000</emis:DerivativeInstrumentsWarrants>
  <emis:NumberOfWarrantsIssued contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1920444" unitRef="shares" decimals="-5" id="id_9160902_8C4EFE81-A58E-4BF5-833A-4E50D18628C6_2001_0">2600000</emis:NumberOfWarrantsIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1921945" unitRef="shares" decimals="-6" id="id_9160902_1F51BE7F-EE09-4543-8A37-9313EB2318AA_1001_0">10000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1921945" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_2001_0">0.56</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1921945" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1936828" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_2001_0">0.56</us-gaap:SharePrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1936828" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_12001_2">2722000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1936828" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_4001_1">1718000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1936828" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_2001_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:BridgeLoan contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1640593x1746595" unitRef="iso4217_USD" decimals="-5" id="id_9160902_C2DB2DA9-3289-49A1-AC88-8F4A45692951_1001_3">2000000</us-gaap:BridgeLoan>
  <us-gaap:ConvertibleNotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1640593x1746595" unitRef="iso4217_USD" decimals="-5" id="id_9160902_C2DB2DA9-3289-49A1-AC88-8F4A45692951_1001_0">43600000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1640593x1746595_1643325x1732774" unitRef="iso4217_USD" decimals="-5" id="id_9160902_C2DB2DA9-3289-49A1-AC88-8F4A45692951_2001_2">700000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1665212" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_1001_3">637000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1732774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_2001_3">0.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1732774" unitRef="pure" decimals="INF" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_2001_1">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1732774" unitRef="iso4217_USD" decimals="INF" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_2001_5">720000</us-gaap:DebtInstrumentFaceAmount>
  <emis:DebtInstrumentAccruedInterest contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1732774" unitRef="iso4217_USD" decimals="-3" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_2001_7">19000</emis:DebtInstrumentAccruedInterest>
  <us-gaap:LoansPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1741680" unitRef="iso4217_USD" decimals="-5" id="id_9160902_C2DB2DA9-3289-49A1-AC88-8F4A45692951_3001_1">21300000</us-gaap:LoansPayable>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1741680" unitRef="iso4217_USD" decimals="INF" id="id_9160902_F9EAE36F-D051-49F4-9D78-016149F87AE3_3001_0">20000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1741680" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_2001_1">21344000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1741680" unitRef="iso4217_USD" decimals="INF" id="id_9160902_6868E01D-D1E3-4DA0-9715-A109A57C82E9_2001_4">21300000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1741680" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_1001_1">21344000</us-gaap:NotesPayable>
  <emis:DebtInstrumentAccruedInterest contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1741680" unitRef="iso4217_USD" decimals="-5" id="id_9160902_6868E01D-D1E3-4DA0-9715-A109A57C82E9_2001_5">700000</emis:DebtInstrumentAccruedInterest>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1755068" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_2001_0">43628000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1755761" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_3001_2">191000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1823297" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_3001_3">1980000</us-gaap:NotesPayable>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1870932" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_4001_2">718000</us-gaap:NotesPayable>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1936828" unitRef="pure" decimals="INF" id="id_9160902_51B24575-9186-41D6-93FB-01EE24397EA3_2002_1">0.13</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1936828" unitRef="iso4217_USD" decimals="INF" id="id_9160902_37052F73-EA57-493C-908C-971C28CBD10E_2001_5">1980000</us-gaap:DebtInstrumentFaceAmount>
  <emis:DebtInstrumentAccruedInterest contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1936828" unitRef="iso4217_USD" decimals="-3" id="id_9160902_37052F73-EA57-493C-908C-971C28CBD10E_2001_7">67000</emis:DebtInstrumentAccruedInterest>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643973x1732474" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_E38E4A31-CBE4-44AE-AF89-766EF527C12D_2001_0">1.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643973x1732474" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_4001_0">36497000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643973x1732474" unitRef="iso4217_USD" decimals="INF" id="id_9160902_E38E4A31-CBE4-44AE-AF89-766EF527C12D_2001_2">43600000</us-gaap:DebtInstrumentFaceAmount>
  <emis:DebtInstrumentAccruedInterest contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643973x1732474" unitRef="iso4217_USD" decimals="-5" id="id_9160902_E38E4A31-CBE4-44AE-AF89-766EF527C12D_2001_3">1400000</emis:DebtInstrumentAccruedInterest>
  <emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionOne contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643986x1636114" unitRef="pure" decimals="2" id="id_9160902_AF009F3E-26BE-49C6-9051-7A343D8A2A8F_2001_1">0.05</emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionOne>
  <emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionTwo contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643986x1636114" unitRef="pure" decimals="3" id="id_9160902_AF009F3E-26BE-49C6-9051-7A343D8A2A8F_2001_2">0.025</emis:PercentageOfRoyaltyPaidOnNetSalesUnderConditionTwo>
  <emis:PercentageOfRoyaltyPaidOnNetSales contextRef="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643986x1636114" unitRef="pure" decimals="2" id="id_9160902_AF009F3E-26BE-49C6-9051-7A343D8A2A8F_2001_0">0.20</emis:PercentageOfRoyaltyPaidOnNetSales>
  <emis:NumberOfWarrantsExercisedByUnrelatedInvestors contextRef="eol_PE5372----1510-Q0007_STD_0_20110112_0_1636324x1920444" unitRef="shares" decimals="-5" id="id_9160902_8C4EFE81-A58E-4BF5-833A-4E50D18628C6_2002_1">200000</emis:NumberOfWarrantsExercisedByUnrelatedInvestors>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_5001_0">11587000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1510-Q0007_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2001_23">4053000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:TreasuryStockShares contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_40">289732</us-gaap:TreasuryStockShares>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_34">400000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_31">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_36">60687478</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_33">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_29">4000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_30">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_35">60977210</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_28">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_37">405531000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_16">239000</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_41">-111950000</us-gaap:StockholdersEquity>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_2_12">29920000</us-gaap:DerivativeLiabilities>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_F65FE63F-019E-434B-9906-8AB918F94AC5_2_1">1262000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_12">1846000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccruedVacationCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_F65FE63F-019E-434B-9906-8AB918F94AC5_2_2">54000</us-gaap:AccruedVacationCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_F65FE63F-019E-434B-9906-8AB918F94AC5_2_0">530000</us-gaap:AccountsPayableCurrent>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_18">44546000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_1002_0">24414000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_38">-514139000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:Liabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_24">117938000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_42">5988000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="INF" id="id_9160902_723E5A9D-1E51-4457-B6B2-830671934A57_2_0">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_21">41616000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_32">610000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_25" />
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_1002_3">603000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_2_5">44546000</us-gaap:NotesPayable>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_17">7633000</us-gaap:LiabilitiesCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_27" />
  <us-gaap:InventoryRawMaterials contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_848B7039-2C8C-4440-A013-75A544E27D8D_1002_0">1350000</us-gaap:InventoryRawMaterials>
  <us-gaap:SecurityDeposit contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_8">24000</us-gaap:SecurityDeposit>
  <us-gaap:Assets contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_9">5988000</us-gaap:Assets>
  <us-gaap:InventoryNet contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_4">2068000</us-gaap:InventoryNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_7">25000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_2_4">7196000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:TreasuryStockValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_39">3952000</us-gaap:TreasuryStockValue>
  <us-gaap:AssetsCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_6">5939000</us-gaap:AssetsCurrent>
  <us-gaap:PrepaidInsurance contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8CC2229C-510A-4C71-9EE9-D4B28A839C3F_2_0">53000</us-gaap:PrepaidInsurance>
  <us-gaap:InventoryWorkInProcess contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_848B7039-2C8C-4440-A013-75A544E27D8D_1002_1">718000</us-gaap:InventoryWorkInProcess>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_5">188000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_2">3683000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_1002_2">628000</us-gaap:PropertyPlantAndEquipmentGross>
  <emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_23">10000</emis:DeferredLeaseLiabilityAndOtherLiabilitiesNonCurrent>
  <emis:PrepaidExpensesAndOtherCurrentAssets contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8CC2229C-510A-4C71-9EE9-D4B28A839C3F_2_2">135000</emis:PrepaidExpensesAndOtherCurrentAssets>
  <emis:DerivativeLiabilitiesRelatedPartyCurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_15">5548000</emis:DerivativeLiabilitiesRelatedPartyCurrent>
  <emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_BB47D61A-7753-41B8-8E06-DBE3268CC3CC_2_20">24133000</emis:RelatedPartyTransactionDerivativeLiabilityNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634505x1633425" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_2002_1">27000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634505x1638371" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D1AFF1BA-E6D8-4694-B1F1-6C85E35B1712_3002_0">601000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634760x1634767" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0EB85DFF-E467-4899-A6D0-292C58158313_1002_2">24414000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634760x1637150" unitRef="iso4217_USD" decimals="-3" id="id_9160902_0EB85DFF-E467-4899-A6D0-292C58158313_1001_2">5506000</us-gaap:DerivativeLiabilities>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1637754" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_2002_0">0.28</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1637754" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1701830" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_1002_7">243000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732474" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_2002_0">0.28</us-gaap:SharePrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732474" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_2002_0">21501000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732474" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_2002_3">2272000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732474" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_2002_1">1.25</emis:FairValueAssumptionConversionPrice>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_2002_0">0.28</us-gaap:SharePrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732774" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_3002_1">705000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732774" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_3002_2">47000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1733630" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_4002_3">930000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1737996" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_2002_0">0.28</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1737996" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_2002_1">1.09</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1737996" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_5002_9">210000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1774308" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_6002_8">750000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1783900" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_7002_4">282000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1802496" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_2002_0">0.28</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1802496" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1821050" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_8002_11">2492000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1830936" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_9002_10">198000</emis:DerivativeInstrumentsWarrants>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1860618" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_10002_5">654000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1920444" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_03E7633C-B5D0-49F2-ABE9-48BE6B27B15D_2001_0">0.28</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1920444" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_03E7633C-B5D0-49F2-ABE9-48BE6B27B15D_2001_1">1.26</emis:FairValueAssumptionConversionPrice>
  <emis:DerivativeInstrumentsWarrants contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1920444" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_11002_6">29000</emis:DerivativeInstrumentsWarrants>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1921945" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_2002_0">0.28</us-gaap:SharePrice>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1921945" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:SharePrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1936828" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_2002_0">0.28</us-gaap:SharePrice>
  <us-gaap:DerivativeLiabilities contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1936828" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DB344294-FBA9-444C-A722-1CD841AAAB60_12002_2">1926000</us-gaap:DerivativeLiabilities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1936828" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_4002_1">221000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <emis:FairValueAssumptionConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1936828" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_2002_1">0.50</emis:FairValueAssumptionConversionPrice>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1665212" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_1002_3">636000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1741680" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_2002_1">8307000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1741680" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_1002_1">8307000</us-gaap:NotesPayable>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1755068" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_2002_0">40897000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1755761" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_3002_2">271000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1823297" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_3002_3">1855000</us-gaap:NotesPayable>
  <us-gaap:NotesPayable contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1870932" unitRef="iso4217_USD" decimals="-3" id="id_9160902_ECB74F83-457D-4B8B-8552-F918DFF7C91C_4002_2">683000</us-gaap:NotesPayable>
  <us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643973x1732474" unitRef="iso4217_USD" decimals="-3" id="id_9160902_D0EE6789-9772-457F-9AEE-CB1CDF4D40EB_4002_0">35332000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
  <us-gaap:DebtInstrumentFaceAmount contextRef="eol_PE5372----1510-Q0007_STD_0_20150106_0_1643325x1741680" unitRef="iso4217_USD" decimals="INF" id="id_9160902_0A31FAF1-8745-4566-A409-490F78A328FF_3003_2">5000000</us-gaap:DebtInstrumentFaceAmount>
  <emis:NumberOfBorrowings contextRef="eol_PE5372----1510-Q0007_STD_1_20140820_0" unitRef="Borrowing" decimals="INF" id="id_9160902_0A31FAF1-8745-4566-A409-490F78A328FF_1_1">5</emis:NumberOfBorrowings>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_1_20150520_0_1633944x1965446_1635457x1641124_1640267x1946637" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_2003_7">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_1_20150520_0_1635457x1641124" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_7003_3">0.48</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_1_20150303_0_1635457x1641124" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_7002_3">0.55</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE5372----1510-Q0007_STD_1_20150930_0_1643325x1732774" unitRef="shares" decimals="INF" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_1002_6">1435717</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE5372----1510-Q0007_STD_1_20150930_0_1643325x1936828" unitRef="shares" decimals="INF" id="id_9160902_37052F73-EA57-493C-908C-971C28CBD10E_1002_6">3959358</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE5372----1510-Q0007_STD_1_20151026_0_1634968x1997496_1636141x1633766" unitRef="iso4217_USD" decimals="-6" id="id_9160902_94E70C68-2900-4AA9-B9E0-456D807B9F8A_1001_1">5000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE5372----1510-Q0007_STD_1_20151026_0_1634968x2002476_1636141x1633766" unitRef="iso4217_USD" decimals="-6" id="id_9160902_94E70C68-2900-4AA9-B9E0-456D807B9F8A_2001_2">9000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE5372----1510-Q0007_STD_1_20151026_0_1636141x1633766" unitRef="iso4217_USD" decimals="-6" id="id_9160902_94E70C68-2900-4AA9-B9E0-456D807B9F8A_3001_0">14000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_18">-5067000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_19">-0.43</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="shares" decimals="0" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_18">-25799000</us-gaap:NetIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_10">43000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_26">3258000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_8">-6004000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_9">154000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_10">8000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_15">-21479000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_4">-16765000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_16">-27483000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_13">-35000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_17">-1684000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_6">203000</us-gaap:ShareBasedCompensation>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_14">4722000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_22">-67000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_7">6004000</us-gaap:OperatingExpenses>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_16">2000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_11">10000</us-gaap:IncreaseDecreaseInSecurityDeposits>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_21">5000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_4">880000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_14">-528000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_5">5113000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_15">-30000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_17">20732000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_6">11000</us-gaap:DepreciationAndAmortization>
  <us-gaap:ProceedsFromLoans contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_20">5000000</us-gaap:ProceedsFromLoans>
  <us-gaap:Depreciation contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_3">11000</us-gaap:Depreciation>
  <emis:NoncashInterestExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_5">4496000</emis:NoncashInterestExpense>
  <emis:IncreaseInDebtDiscountForNewDerivatives contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_2_27">966000</emis:IncreaseInDebtDiscountForNewDerivatives>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_4_12">-16730000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1637754" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60EADD80-ABFF-40AB-9C13-AB0DD87F361A_1004_0">2300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1732474" unitRef="iso4217_USD" decimals="-5" id="id_9160902_70C83B15-F7C0-4D14-8F49-4D169AEA98F4_1004_0">10700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1732774" unitRef="iso4217_USD" decimals="-5" id="id_9160902_869A1765-D840-4EA2-8C93-07661187CDB7_1004_700001">900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1802496" unitRef="iso4217_USD" decimals="-3" id="id_9160902_5D88D9BA-E3CD-4799-890D-94F2D2BD63B5_1004_0">102000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:FairValueOfWarrantsIncreased contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1824912" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60DCB710-7769-4813-9F68-1337611475B5_1004_0">100000</emis:FairValueOfWarrantsIncreased>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1920444" unitRef="iso4217_USD" decimals="-3" id="id_9160902_520B2E6E-3AD8-41FE-8B06-98CCE3472547_1004_1">62000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsIncreased contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1921945" unitRef="iso4217_USD" decimals="-5" id="id_9160902_6EDA1CFC-F930-43C6-A1C1-AEC2D7DEFA8D_1004_1">1900000</emis:FairValueOfWarrantsIncreased>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1936828" unitRef="iso4217_USD" decimals="-5" id="id_9160902_5FEBBCEF-C0E2-4062-B1A3-60C51857BE2A_1004_0">1000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_56F9EA02-4353-4A2E-933F-BDECD0242E50_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_18">-14279000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_701523FA-32C2-4544-B593-B436AEBF5A78_3_2">P6Y9M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:LineOfCreditFacilityDescription contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_E9E2AE88-E2D9-4458-A7CE-8F9D15B69438_1_0">Loan will mature on the earlier of (a) December 31, 2019 and, (b) 30 days  after the end of any fiscal year in which the Company&apos;s cash (plus certain cash  expenditures during such fiscal year that are unrelated to the B12 Product or  related products) as of the end of such fiscal year (subject to certain  permitted deductions) is more than three times the principal amount of the Loan  as of the end of such fiscal year.</us-gaap:LineOfCreditFacilityDescription>
  <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_D7CFECA8-4839-4C9E-850C-95BEE75E37D3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Derivative instruments consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;987&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,722&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,926&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2009 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;930&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated June 2010 MHR Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;282&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;654&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 August 2010 Investor Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;464&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,432&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 July 2011 Investor Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;198&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 May 2013 MHR Modification Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,757&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
  <us-gaap:AccountingChangesAndErrorCorrectionsTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_6A56F118-2E9D-48C4-97FC-58391E20F0F0_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;13. New Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2015, the FASB issued ASU
 No.&amp;#xA0;2015-11,&amp;#xA0;&amp;#x201C;Simplifying the Measurement of
 Inventory&amp;#x201D; (&amp;#x201C;ASU 2015-11&amp;#x201D;). ASU 2015-11 requires
 that inventory within the scope of the guidance be measured at the
 lower of cost and net realizable value. Inventory measured using
 last-in, first-out (LIFO) and retail inventory method (RIM) are
 excluded from this new guidance. This ASU replaces the concept of
 market with the single measurement of net realizable value and is
 intended to create efficiencies for preparers and more closely
 aligns U.S. GAAP with IFRS. This ASU is effective for public
 business entities in fiscal years beginning after December&amp;#xA0;15,
 2016, including interim periods within those years. Prospective
 application is required and early adoption is permitted as of the
 beginning of an interim or annual reporting period. The Company is
 currently evaluating the impact of the new standards.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In April&amp;#xA0;2015, the FASB issued ASU 2015-03, &amp;#x201C;Interest
 &amp;#x2013; Imputation of Interest&amp;#x201D; (&amp;#x201C;ASU 2015-03&amp;#x201D;),
 which requires that debt issuance costs related to a recognized
 debt liability be presented in the balance sheet as a direct
 deduction from the carrying amount of that debt liability,
 consistent with debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this ASU. ASU 2015-03 is effective for annual and interim
 periods beginning on or after December&amp;#xA0;15, 2015. The adoption
 of ASU 2015-03 is not expected to have a material impact on our
 financial position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &amp;#x201C;Revenue
 from Contracts with Customers&amp;#x201D; (&amp;#x201C;ASU 2014-09&amp;#x201D;),
 which requires entities to recognize revenue in a way that depicts
 the transfer of promised goods or services to customers in an
 amount that reflects the consideration to which the entity expects
 to be entitled to in exchange for those goods or services. The new
 guidance also requires additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. In July 2015, the FASB voted to delay
 the effective date of ASU 2014-09 by one year to the first quarter
 of 2018 to provide companies sufficient time to implement the
 standards. Early adoption will be permitted, but not before the
 first quarter of 2017. Adoption can occur using one of two
 prescribed transition methods. The Company is currently evaluating
 the impact of the new standard.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &amp;#x201C;Disclosure of Uncertainties About an Entity&amp;#x2019;s Ability
 to Continue as a Going Concern&amp;#x201D; (&amp;#x201C;ASU 2014-15&amp;#x201D;),
 which provides guidance on management&amp;#x2019;s responsibility in
 evaluating whether there is substantial doubt about an
 entity&amp;#x2019;s ability to continue as a going concern and to
 provide related footnote disclosures. ASU 2014-15 is effective for
 the annual period ending after December&amp;#xA0;15, 2016, and for
 annual and interim periods thereafter. The adoption of ASU 2014-15
 is not expected to have a material impact on our financial
 position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Management does not believe there would have been a material effect
 on the accompanying financial statements had any other recently
 issued, but not yet effective, accounting standards been adopted in
 the current period.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:AccountingChangesAndErrorCorrectionsTextBlock>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_E36CF798-3986-4A66-A664-4E89FF67CD26_1_0">2014-08-20</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_56F9EA02-4353-4A2E-933F-BDECD0242E50_1_3">2015</dei:DocumentFiscalYearFocus>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_79619D5A-3B70-4413-9613-0E7820FDDEAC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes the changes in fair value of the
 Company&amp;#x2019;s Level 3 financial instruments for the periods ended
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the Bridge
 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;221&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative liability of the embedded conversion feature of the
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,287&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_56F9EA02-4353-4A2E-933F-BDECD0242E50_1_1">false</dei:AmendmentFlag>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_0E43670F-8CD8-4715-BB48-ADF2E5F4A2E9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 We recognize revenue in accordance with FASB ASC 605-10-S99,
 &lt;i&gt;Revenue Recognition.&lt;/i&gt; We sell our oral Eligen B12&amp;#x2122; Rx
 product through drug wholesalers and retail pharmacies. We
 recognize revenue from prescription product sales, net of sales
 discounts, chargebacks, and rebates. We accept returns of unsalable
 product from customers within a return period of six months prior
 to and 12 months following product expiration. Our oral Eligen
 B12&amp;#x2122; Rx product currently has a shelf life of 24 months from
 the date of manufacture. Given the limited history of our Oral
 Eligen B12&amp;#x2122; Rx product, we currently cannot reliably estimate
 expected returns of the product at the time of shipment.
 Accordingly, we defer recognition of revenue on prescription
 products until the right of return no longer exists, which occurs
 at the earlier of the time the oral Eligen B12&amp;#x2122; Rx product is
 dispensed through patient prescriptions or expiration of the right
 of return.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_CCB8FB2B-2F4C-493F-8EE5-549134B07CBA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;9. Notes Payable&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Notes payable, net of related discounts, consists of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Second Amended and Restated Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,497&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Second Amended and Restated Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;271&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Second Amended and Restated Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;636&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Non-current notes payable, net of related discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58,669&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 On August&amp;#xA0;20, 2014, the Company entered into a series of
 agreements (the &amp;#x201C;Transaction Documents&amp;#x201D;) with MHR
 Capital Partners Master Account LP, MHR Capital Partners
 (100)&amp;#xA0;LP, MHR Institutional Partners II LP, and MHR
 Institutional Partners IIA LP, (collectively, &amp;#x201C;MHR&amp;#x201D; or
 the &amp;#x201C;Lenders&amp;#x201D;), for a new loan facility (the
 &amp;#x201C;Loan Agreement&amp;#x201D;), an extension of the Company&amp;#x2019;s
 existing obligations under various promissory notes previously
 issued to the Lenders, and for payment by the Company of certain
 royalties to MHR (the &amp;#x201C;Transaction&amp;#x201D;).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Loan Agreement provides for, among other things, a commitment
 (the &amp;#x201C;Commitment&amp;#x201D;) of the Lenders to loan the Company
 up to $20 million to finance the development, manufacturing,
 marketing and sale of oral Eligen &lt;sup style="FONT-SIZE: 85%; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt; B12 (the
 &amp;#x201C;B12 Product&amp;#x201D;). The Company may make five borrowings
 (each, a &amp;#x201C;Borrowing&amp;#x201D;, and collectively, the
 &amp;#x201C;Loan&amp;#x201D;) under the Loan Agreement. The first borrowing
 under the Loan Agreement occurred on August&amp;#xA0;20, 2014, in an
 original principal amount of $5.0 million, the second occurred on
 November&amp;#xA0;4, 2014 in an original principal amount of $3.0
 million, the third occurred on January&amp;#xA0;6, 2015 in an original
 principal amount of $5.0 million, the fourth occurred on
 April&amp;#xA0;6, 2015 in an original principal amount of $5.0 million,
 and the fifth and final borrowing occurred on July&amp;#xA0;1, 2015 in
 an original principal amount of $2.0 million. In addition, as
 described below, if the Company does not have sufficient cash in
 excess of the Minimum Cash Balance, as defined below, to pay any
 Royalties that become due under the Royalty Agreement, as described
 below, such Royalties will be paid as an additional Loan under the
 Loan Agreement by increasing the principal amount outstanding under
 the Loan Agreement (any such Loan, &amp;#x201C;Paid-In-Kind
 Royalties&amp;#x201D;). The &amp;#x201C;Minimum Cash Balance&amp;#x201D; generally
 means cash on hand (plus certain cash expenditures during such
 fiscal year that are unrelated to the B12 Product or related
 products) of at least $10 million (or $15 million, under certain
 circumstances beginning as early as October&amp;#xA0;1, 2015), subject
 to certain permitted deductions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Except with respect to Paid-In-Kind Royalties incurred under the
 Loan Agreement after all amounts of principal and interest have
 previously been paid in full, the Loan will mature on the earlier
 of (a)&amp;#xA0;December&amp;#xA0;31, 2019 and, (b)&amp;#xA0;30 days after the
 end of any fiscal year in which the Company&amp;#x2019;s cash (plus
 certain cash expenditures during such fiscal year that are
 unrelated to the B12 Product or related products) as of the end of
 such fiscal year (subject to certain permitted deductions) is more
 than three times the principal amount of the Loan as of the end of
 such fiscal year. Paid-In-Kind Royalties incurred under the Loan
 Agreement after all amounts of principal and interest have
 previously been paid in full mature one year following the date of
 incurrence. The Loan bears interest at a rate of 13%&amp;#xA0;per annum
 (the &amp;#x201C;Interest Rate&amp;#x201D;), compounded monthly, and will be
 payable in kind and in arrears on June&amp;#xA0;30 and December&amp;#xA0;31
 of each year up to and including the maturity date by increasing
 the outstanding principal amount of the Loan by the amount of each
 such interest payment. So long as an event of default under the
 Loan Agreement (an &amp;#x201C;Event of Default&amp;#x201D;) has occurred and
 is continuing, at the election of MHR, interest shall accrue on the
 Loan at a rate equal to 2%&amp;#xA0;per annum above the Interest Rate
 (&amp;#x201C;Default Rate&amp;#x201D;). Interest at the Default Rate shall
 accrue from the initial date of such Event of Default until that
 Event of Default is cured or waived in writing and shall be payable
 upon demand and, if not paid when due, shall itself bear interest
 at the Default Rate. The Loan must be repaid from time to time
 prior to maturity pursuant to (a)&amp;#xA0;a cash sweep of 50% of the
 Company&amp;#x2019;s adjusted consolidated free cash flow, or 75% of the
 Company&amp;#x2019;s adjusted consolidated free cash flow in any year in
 which the adjusted consolidated free cash flow exceeds $50 million,
 to the extent such cash sweep does not cause the Company&amp;#x2019;s
 cash as of the end of such year to be less than the Minimum Cash
 Balance, (b)&amp;#xA0;a cash sweep of 50% of any cash proceeds received
 from any third party in connection with the license, distribution
 or sale of any of the Company&amp;#x2019;s products other than the B12
 Product or related products (the &amp;#x201C;Non-B12 Products&amp;#x201D;),
 subject to the priority described below, and (c)&amp;#xA0;a Royalty
 Match (as described below), to the extent such Royalty Match does
 not cause the Company&amp;#x2019;s cash as of the end of such year to be
 less than the Minimum Cash Balance and subject to the priority
 described below. The Loan Agreement provides for certain
 representations and warranties, conditions precedent to the
 Lenders&amp;#x2019; obligation to lend, affirmative and negative
 covenants of the Company (including, but not limited to, certain
 milestones in the development of its B12 Products) and Events of
 Default. If we fail to meet our obligations under the terms of the
 Loan Agreement, or fail to meet any of the net sales targets
 included in the Loan Agreement, we would be in default under these
 notes, which would give MHR the option of foreclosing on
 substantially all of our assets. On November&amp;#xA0;10, 2015, MHR
 agreed to waive any event of default resulting from the failure to
 satisfy the December&amp;#xA0;31, 2015 net sales target specified in
 the Loan Agreement. As of September&amp;#xA0;30, 2015, the principal
 balance and accrued interest of the Loan Agreement was $21.3
 million and $0.7 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In connection with the entry into the Loan Agreement, on
 August&amp;#xA0;20, 2014, the Lenders and the Company further amended
 and restated (i)&amp;#xA0;the Convertible Notes issued by the Company
 to certain of the Lenders, (ii)&amp;#xA0;the Bridge Notes issued by the
 Company to certain of the Lenders, and (iii)&amp;#xA0;the Reimbursement
 Notes (and, together with the Convertible Notes and Bridge Notes,
 the &amp;#x201C;MHR Notes&amp;#x201D;). Also, in connection with the entry
 into the Loan Agreement and the amendment and restatement of the
 MHR Notes, Institutional Partners IIA and the Company have amended
 the Pledge and Security Agreement, dated September&amp;#xA0;26, 2005,
 as amended, by and between the Company and Institutional Partners
 IIA to, among other things, secure the Reimbursement Notes and
 payments due under the Loan Agreement with substantially all of the
 Company&amp;#x2019;s assets, and secure the payments due under the
 Royalty Agreement and Paid-In-Kind Royalties due under the Loan
 Agreement with the Company&amp;#x2019;s intellectual property relating
 to the B12 Products and related products.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Convertible Notes.&lt;/b&gt; On September&amp;#xA0;26, 2005, we received
 net proceeds of approximately $12.9 million under a
 $15&amp;#xA0;million secured loan agreement (the &amp;#x201C;2005 Loan
 Agreement&amp;#x201D;) executed with MHR. Under the 2005 Loan Agreement,
 MHR requested, and on May&amp;#xA0;16, 2006, we effected, the exchange
 of the loan from MHR for the predecessor of the Convertible Notes,
 which were 11% senior secured convertible notes with substantially
 the same terms as the 2005 Loan Agreement, except that the original
 Convertible Notes were convertible, at the sole discretion of MHR,
 into shares of our common stock at a price per share of $3.78. In
 connection with the original Convertible Notes exchange, the
 Company agreed to appoint a representative of MHR (the &amp;#x201C;MHR
 Nominee&amp;#x201D;) and another person (the &amp;#x201C;Mutual
 Director&amp;#x201D;) to the Board. Further, the Company agreed to
 amend, and in January 2006 did amend, its certificate of
 incorporation to provide for continuity of the MHR Nominee and the
 Mutual Nominee on the Board so long as MHR holds at least 2% of the
 outstanding common stock of the Company. The original Convertible
 Notes were amended and restated on May&amp;#xA0;7, 2013 and as
 described above, amended and restated a second time on
 August&amp;#xA0;20, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Convertible Notes now provide for a new maturity date of
 March&amp;#xA0;31, 2022 (subject to acceleration upon the occurrence of
 certain specified events of default, including the failure to meet
 certain sales, performance, and manufacturing milestones specified
 in the Convertible Notes). The interest rate is 13%&amp;#xA0;per annum,
 compounded monthly, which interest will be payable in the form of
 additional Convertible Notes. The Convertible Notes are
 collateralized by a first priority lien in favor of the Lenders on
 substantially all of the Company&amp;#x2019;s assets. After all
 principal and interest under the Loan Agreement and Reimbursement
 Notes are repaid, the remaining Convertible Notes must be redeemed
 from time to time prior to maturity pursuant to a cash sweep of 50%
 of the Company&amp;#x2019;s adjusted consolidated free cash flow (75% of
 the Company&amp;#x2019;s adjusted consolidated free cash flow in any
 year in which the Company&amp;#x2019;s adjusted consolidated free cash
 flow exceeds $50 million) to the extent such cash sweep does not
 cause the Company&amp;#x2019;s cash as of the end of such year to be
 less than the Minimum Cash Balance. The Convertible Notes are
 convertible, at the option of the holders, at a conversion price of
 $1.25 per share of common stock, which conversion price is subject
 to adjustment upon the occurrence of specified events, including
 stock dividends, stock splits, certain fundamental corporate
 transactions, and certain issuances of common stock by the Company.
 The Convertible Notes must also be redeemed from time to time prior
 to maturity pursuant to (a)&amp;#xA0;a cash sweep of 50% of any cash
 proceeds received from any third party in connection with the
 license, distribution or sale of any Non-B12 Product, subject to
 the priority described below and (b)&amp;#xA0;a Royalty Match (as
 described below), to the extent such Royalty Match does not cause
 the Company&amp;#x2019;s cash as of the end of such year to be less than
 the Minimum Cash Balance and subject to the priority described
 below. If we fail to meet our obligations under the terms of the
 Convertible Notes, or fail to meet any of the net sales targets
 included in the Convertible Notes, we would be in default under
 these notes, which would give MHR the option of foreclosing on
 substantially all of our assets. On November&amp;#xA0;10, 2015, MHR
 agree to waive any event of default resulting from the failure to
 satisfy the December&amp;#xA0;31, 2015 net sales target specified in
 the Convertible Notes. As of September&amp;#xA0;30, 2015, the principal
 balance and accrued interest of the Convertible Notes were $43.6
 million and $1.4 million, respectively; and the Convertible Notes
 were convertible into 34,902,557 shares of our common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Reimbursement Notes.&lt;/b&gt; On June&amp;#xA0;8, 2010, the Company
 issued the predecessor to the Reimbursement Notes to MHR in the
 form of certain non-interest bearing promissory notes in the
 aggregate principal amount of $600,000 in reimbursement for legal
 expenses incurred by MHR in connection with MHR&amp;#x2019;s agreement
 to, among other things, waive certain rights as a senior secured
 party of the Company and enter into a non-disturbance agreement
 with the Company&amp;#x2019;s collaboration partner, Novartis Pharma AG,
 and, if necessary, to enter into a comparable agreement in
 connection with another potential Company transaction. The original
 Reimbursement Notes were amended and restated on May&amp;#xA0;7, 2013
 and, as described above, amended and restated again on
 August&amp;#xA0;20, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Reimbursement Notes provide for a maturity date of the earlier
 of (a)&amp;#xA0;March&amp;#xA0;31, 2022 and (b)&amp;#xA0;immediately prior to
 the time that any amounts outstanding under the Loan Agreement are
 repaid (subject to acceleration upon the occurrence of certain
 events of default specified in the Reimbursement Notes), and bear
 interest at the rate of 10%&amp;#xA0;per annum, compounded monthly,
 which interest is payable in the form of additional Reimbursement
 Notes. The Reimbursement Notes are collateralized by a first
 priority lien in favor of the Lenders on substantially all of the
 Company&amp;#x2019;s assets. The Reimbursement Notes are convertible, at
 the option of the holders, at a conversion price of $0.50 per share
 of common stock, which conversion price is subject to adjustment
 upon the occurrence of specified events, including stock dividends,
 stock splits, certain fundamental corporate transactions, and
 certain issuances of common stock by the Company. The Reimbursement
 Notes must also be redeemed from time to time prior to maturity
 pursuant to a cash sweep of 50% of any cash proceeds received from
 any third party in connection with the license, distribution or
 sale of any Non-B12 Product, subject to the priority described
 below. As of September&amp;#xA0;30, 2015, the principal balance and
 accrued interest of the Reimbursement Notes were $0.72 million and
 $19 thousand, respectively; and the Reimbursement Notes were
 convertible into 1,435,717 shares of our common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &lt;b&gt;Bridge Notes.&lt;/b&gt; On October&amp;#xA0;17, 2012, the Company issued
 to MHR the predecessor to the Bridge Notes in the aggregate
 principal amount of $1,400,000. The original Bridge Notes provided
 for an interest rate of 13%&amp;#xA0;per annum and were payable on
 demand. The Bridge Notes were amended and restated on May&amp;#xA0;7,
 2013 and restated again on August&amp;#xA0;20, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Bridge Notes provide for a maturity date of March&amp;#xA0;31, 2022
 (subject to acceleration upon the occurrence of certain events of
 default specified) and bear interest at 13%&amp;#xA0;per year,
 compounded monthly and payable in the form of additional Bridge
 Notes. The Bridge Notes are collateralized by a first priority lien
 in favor of the Lenders on substantially all of the Company&amp;#x2019;s
 assets. The Bridge Notes are convertible, at the option of the
 holders, at a conversion price of $0.50 per share of common stock,
 which conversion price is subject to adjustment upon the occurrence
 of specified events, including stock dividends, stock splits,
 certain fundamental corporate transactions, and certain issuances
 of common stock by the Company. The Bridge Notes must also be
 redeemed from time to time prior to maturity pursuant to (a)&amp;#xA0;a
 cash sweep of 50% of any cash proceeds received from any third
 party in connection with the license, distribution or sale of any
 Non-B12 Product, subject to the priority described below and
 (b)&amp;#xA0;a Royalty Match (as described below), to the extent such
 Royalty Match does not cause the Company&amp;#x2019;s cash as of the end
 of such year to be less than the Minimum Cash Balance and subject
 to the priority described below. As of September&amp;#xA0;30, 2015, the
 principal balance and accrued interest of the Bridge Notes were
 $1.98 million and $67 thousand, respectively; and the Bridge Notes
 were convertible into 3,959,358 shares of our common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The priority of the cash sweep for Non-B12 Products is as follows:
 (i)&amp;#xA0;to redeem the Reimbursement Notes, (ii)&amp;#xA0;to prepay
 principal and interest outstanding under the Loan Agreement;
 (iii)&amp;#xA0;to reduce the Commitment; (iv)&amp;#xA0;to redeem the
 Convertible Notes; and (v)&amp;#xA0;to redeem the Bridge Notes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a condition to MHR entering into the Loan Agreement and amending
 and restating the MHR Notes, the Company and MHR entered into a
 Royalty Agreement (the &amp;#x201C;Royalty Agreement&amp;#x201D;) on
 August&amp;#xA0;20, 2014 pursuant to which the Company agreed to pay to
 MHR, subject to specified terms and conditions, royalties in
 perpetuity (the &amp;#x201C;Royalties&amp;#x201D;), commencing as of the date
 of the Royalty Agreement, in an amount equal to: twenty percent
 (20%)&amp;#xA0;of all Net Product Sales (as defined in the Royalty
 Agreement) and any third party payments arising in connection with
 the sale of the B12 Product and related products, during any fiscal
 year; provided that, from and after October&amp;#xA0;1, 2015, if no
 amount of indebtedness is outstanding under the Loan Agreement (the
 &amp;#x201C;Indebtedness Repayment Condition&amp;#x201D;), such amount shall
 be reduced to (i)&amp;#xA0;five percent (5%)&amp;#xA0;of all Net Sales and
 third party payments commencing with the first quarter immediately
 following the quarter in which the Indebtedness Repayment Condition
 is satisfied, or (ii)&amp;#xA0;two and one half percent (2.5%)&amp;#xA0;of
 all Net Sales commencing with the quarter immediately following the
 quarter in which the Indebtedness Repayment Condition is satisfied,
 but only with respect to the Net Sales made in any country in which
 there was not a Valid Patent Claim (as defined in the Royalty
 Agreement) and where generic entry of a competitive product not by
 the Company or its affiliates that does not infringe a Valid Patent
 Claim in such country has occurred, in each case as of the last day
 of such Fiscal Quarter. Once the royalty rate has been reduced to
 5%, the rate shall not be reinstated to 20% even if amounts become
 outstanding under the Loan Agreement as a result of Paid-In-Kind
 Royalties. Payments of Royalties shall be made in cash to the
 extent such Royalties do not cause the Company&amp;#x2019;s cash as of
 the end of any year to be less than the Minimum Cash Balance, and
 otherwise shall be paid as Paid-In-Kind Royalties.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 If any Royalties become due under the Royalty Agreement when the
 royalty rate is 5% or 2.5%, the amount outstanding under the Loan
 Agreement, Convertible Notes and Bridge Notes shall be reduced in
 an amount equal to such royalty payment, to the extent such payment
 does not cause the Company&amp;#x2019;s cash as of the end of such year
 to be less than the Minimum Cash Balance (the &amp;#x201C;Royalty
 Match&amp;#x201D;), in the following priority: (i)&amp;#xA0;first, to prepay
 the Loan; (ii)&amp;#xA0;second, to redeem the Convertible Notes; and
 (iii)&amp;#xA0;finally, to redeem the Bridge Notes. For the nine months
 ended September&amp;#xA0;30, 2015, the Company recorded $121 thousand
 royalty expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Additional fees paid by Emisphere in connection with the Loan
 Agreement, MHR Notes and the Royalty Agreement included the
 reimbursement of $225 thousand of MHR&amp;#x2019;s professional fees
 associated with the transaction, which was recorded as interest
 expense during the third quarter of 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 We accounted for the modifications to our obligations to MHR
 evidenced by the MHR Notes as a troubled debt restructuring under
 FASB ASC 470-60. As there was only a modification of terms to the
 existing debt and we did not transfer any assets or equity in a
 settlement to MHR no gain or loss was recorded on the transaction.
 The change in cash outflows resulting from the modification of
 terms are accounted for on a prospective basis.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The carrying value of the MHR Notes is comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,980&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unamortized discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,196&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58,669&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_19">-0.50</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:DebtInstrumentDescription contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_69B09641-FF02-4997-8871-81CE92C84D44_1_0">On August 20, 2014, the  Lenders and the Company further amended and restated (i) the Convertible Notes  issued by the Company to certain of the Lenders, (ii) the Bridge Notes issued by  the Company to certain of the Lenders, and (iii) the Reimbursement Notes (and,  together with the Convertible Notes and Bridge Notes, the "MHR Notes").</us-gaap:DebtInstrumentDescription>
  <dei:DocumentType contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_56F9EA02-4353-4A2E-933F-BDECD0242E50_1_0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_46C9DFF1-11EF-4B62-A749-FDE81E2D8BE5_1_2">0000805326</dei:EntityCentralIndexKey>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_A31748E4-2779-490F-8A4F-A2F89BEA3D46_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid expenses and other current assets consist of the
 following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid corporate insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Deposit on inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;501&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;135&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;722&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <dei:EntityFilerCategory contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_46C9DFF1-11EF-4B62-A749-FDE81E2D8BE5_1_4">Smaller Reporting Company</dei:EntityFilerCategory>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_DEAF6890-3D3A-41F5-99F4-B34B85CB7384_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;8. Accounts Payable and Accrued Expenses&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts payable and accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;859&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;530&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued legal, professional and other fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;743&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,262&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued vacation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,672&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,846&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_B342988C-6FC9-4ACC-B9F1-405254392720_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;2. Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The condensed balance sheet at December&amp;#xA0;31, 2014 was derived
 from audited financial statements but does not include all
 disclosures required by accounting principles generally accepted in
 the United States of America. The other information in these
 condensed financial statements is unaudited but, in the opinion of
 management, reflects all adjustments necessary for a fair
 presentation of the results for the periods covered. All such
 adjustments are of a normal recurring nature unless disclosed
 otherwise. These condensed financial statements, including notes,
 have been prepared in accordance with the applicable rules of the
 Securities and Exchange Commission (the &amp;#x201C;SEC&amp;#x201D;) and do
 not include all of the information and disclosures required by
 accounting principles generally accepted in the United States of
 America for complete financial statements. These condensed
 financial statements should be read in conjunction with the
 financial statements and additional information as contained in our
 Annual Report on Form 10-K for the year ended December&amp;#xA0;31,
 2014. Results of operations for the nine-month period ended
 September&amp;#xA0;30, 2015 are not necessarily indicative of the
 operating results that may be expected for the year ending
 December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_85B5854C-3B61-4FF0-A445-3C62E05E0D22_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts payable and accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accounts payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;859&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;530&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued legal, professional and other fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;743&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,262&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued vacation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;54&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,672&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,846&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_1_4">4998000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_34746D78-4E56-4DBA-9D43-E74766AA13EB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;7. Equipment and Leasehold Improvements, Net&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Lives&lt;br /&gt;
 in Years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;3-7&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;Term&amp;#xA0;of&amp;#xA0;lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equipment and leasehold improvements, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_30148770-395B-45B4-95D5-361947A8E8BC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;14. Fair Value&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In accordance with FASB ASC 820, &lt;i&gt;&amp;#x201C;Fair Value Measurements
 and Disclosures,&amp;#x201D;&lt;/i&gt; the following table represents the
 Company&amp;#x2019;s fair value hierarchy for its financial assets and
 liabilities measured at fair value on a recurring basis as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;September&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 66.85pt"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,479&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 64.65pt"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,506&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Level 3 financial instruments consist of certain common stock
 warrants and embedded conversion features. The fair value of these
 warrants and embedded conversion features that have exercise reset
 features are estimated using a Monte Carlo valuation model. The
 unobservable input used by the Company was the estimation of the
 likelihood of a reset occurring on the embedded conversion feature
 of the Amended and Restated Convertible Notes, the embedded
 conversion feature of the Amended and Restated Reimbursement Notes,
 the embedded conversion feature of the Amended and Restated Bridge
 Notes, and the embedded conversion feature of the Amended and
 Restated September 2010 Warrants. These estimates of the likelihood
 of completing an equity raise that would meet the criteria to
 trigger the reset provisions are based on numerous factors,
 including the remaining term of the financial instruments and the
 Company&amp;#x2019;s overall financial condition.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table summarizes the changes in fair value of the
 Company&amp;#x2019;s Level 3 financial instruments for the periods ended
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Beginning Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,587&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the Bridge
 Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;221&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative liability of embedded conversion feature of the
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;47&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative liability of the embedded conversion feature of the
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;177&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,272&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,998&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,287&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Ending Balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Changes in the unobservable input values would likely cause
 material changes in the fair value of the Company&amp;#x2019;s Level 3
 financial instruments. The significant unobservable input used in
 the fair value measurement is the estimation of the likelihood of
 the occurrence of a change to the contractual terms of the
 financial instruments. A significant increase (decrease) in this
 likelihood would result in a higher (lower) fair value
 measurement.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_D95BBE02-96FA-4D90-8F3A-07EE84B77976_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The carrying value of the MHR Notes is comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;40,897&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;718&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;683&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,980&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,855&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Unamortized discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,196&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58,669&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="INF" id="id_9160902_701523FA-32C2-4544-B593-B436AEBF5A78_2_1">1.4895</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_D8B2C6F4-9DAD-4275-ABF6-9177176D2297_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;Useful&amp;#xA0;Lives&lt;br /&gt;
 in Years&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;b&gt;3-7&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;601&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;
 &lt;b&gt;Term&amp;#xA0;of&amp;#xA0;lease&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Less: accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;613&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;603&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Equipment and leasehold improvements, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_202B60F0-6DA5-41DD-A598-6DC225E295BC_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Inventory consists of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Raw Materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,350&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;718&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Finished Goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,494&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,054&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,068&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="2" id="id_9160902_701523FA-32C2-4544-B593-B436AEBF5A78_3_5">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_46C9DFF1-11EF-4B62-A749-FDE81E2D8BE5_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityRegistrantName contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_46C9DFF1-11EF-4B62-A749-FDE81E2D8BE5_1_1">EMISPHERE TECHNOLOGIES INC</dei:EntityRegistrantName>
  <us-gaap:InventoryDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_04EA7E2E-71A8-4F88-9C40-D687CDCD9D8F_1_0">&lt;div&gt;
 &lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;5. Inventory&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Inventory consists of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Raw Materials&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;560&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,350&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Work-in-process&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;718&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Finished Goods&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,494&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,054&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,068&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_BA6D3E90-D48B-4B48-ACF2-EA946B93EEBA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 the following table represents the Company&amp;#x2019;s fair value
 hierarchy for its financial assets and liabilities measured at fair
 value on a recurring basis as of September&amp;#xA0;30, 2015 and
 December&amp;#xA0;31, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;September&amp;#xA0;30, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt; WIDTH: 66.85pt"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,479&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31,357&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="4"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 64.65pt"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2014&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Derivative Instruments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,506&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,414&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_E94F183B-38FC-412C-9D47-7701A5E6D8AD_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;12. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company is primarily subject to United States federal and New
 Jersey state income tax. The Company&amp;#x2019;s policy is to recognize
 interest and penalties related to income tax matters in income tax
 expense. As of December&amp;#xA0;31, 2014 and September&amp;#xA0;30, 2015,
 the Company had no accruals for interest or penalties related to
 income tax matters.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_24255F0B-A34C-4AF1-9483-F056E63CBE93_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;11. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Commitments.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 We lease office space at 4 Becker Farm Road, Roseland, New Jersey
 under a non-cancellable operating lease expiring in 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As of September&amp;#xA0;30, 2015, future minimum rental payments are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 95.55pt"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015 (remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;253&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company evaluates the financial consequences of legal actions
 periodically or as facts present themselves and records accruals to
 account for its best estimate of future costs accordingly.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Contingencies.&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In the ordinary course of business, we enter into agreements with
 third parties that include indemnification provisions which, in our
 judgment, are normal and customary for companies in our industry
 sector. These agreements are typically with business partners,
 clinical sites, and suppliers. Pursuant to these agreements, we
 generally agree to indemnify, hold harmless, and reimburse
 indemnified parties for losses suffered or incurred by the
 indemnified parties with respect to our product candidates, use of
 such product candidates, or other actions taken or omitted by us.
 The maximum potential amount of future payments we could be
 required to make under these indemnification provisions is
 unlimited. We have not incurred material costs to defend lawsuits
 or settle claims related to these indemnification provisions. As a
 result, the estimated fair value of liabilities relating to these
 provisions is minimal. Accordingly, we have no liabilities recorded
 for these provisions as of September&amp;#xA0;30, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In the normal course of business, we may be confronted with issues
 or events that may result in a contingent liability. These
 generally relate to lawsuits, claims, environmental actions or the
 action of various regulatory agencies. If necessary, management
 consults with counsel and other appropriate experts to assess any
 matters that arise. If, in our opinion, we have incurred a probable
 loss as set forth by accounting principles generally accepted in
 the U.S., an estimate is made of the loss and the appropriate
 accounting entries are reflected in our financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As a condition to MHR entering into the Loan Agreement and amending
 and restating the MHR Notes, the Company and MHR entered into a
 Royalty Agreement (the &amp;#x201C;Royalty Agreement&amp;#x201D;) on
 August&amp;#xA0;20, 2014 providing for the payment by the Company to
 MHR of certain royalties on the terms and conditions set forth
 therein (see Note 9).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under the terms of the Royalty Agreement, the Company agreed to pay
 to MHR, subject to the terms and conditions of the Royalty
 Agreement, royalties in perpetuity (the &amp;#x201C;Royalties&amp;#x201D;),
 commencing as of the date of the Royalty Agreement, in an amount
 equal to: twenty percent (20%)&amp;#xA0;of all Net Product Sales (as
 defined in the Royalty Agreement) and any third party payments
 arising in connection with the sale of the B12 Product and related
 products, during any fiscal year; provided that, from and after
 October&amp;#xA0;1, 2015, if no amount of indebtedness is outstanding
 under the Loan Agreement (the &amp;#x201C;Indebtedness Repayment
 Condition&amp;#x201D;), such amount shall be reduced to (i)&amp;#xA0;five
 percent (5%)&amp;#xA0;of all Net Sales and third party payments
 commencing with the first quarter immediately following the quarter
 in which the Indebtedness Repayment Condition is satisfied, or
 (ii)&amp;#xA0;two and one half percent (2.5%)&amp;#xA0;of all Net Sales
 commencing with the quarter immediately following the quarter in
 which the Indebtedness Repayment Condition is satisfied, but only
 with respect to the Net Sales made in any country in which there
 was not a Valid Patent Claim (as defined in the Royalty Agreement)
 and where generic entry of a competitive product not by the Company
 or its affiliates that does not infringe a Valid Patent Claim in
 such country has occurred, in each case as of the last day of such
 Fiscal Quarter. Once the royalty rate has been reduced to 5%, the
 rate shall not be reinstated to 20% even if amounts become
 outstanding under the Loan Agreement as a result of Paid-In-Kind
 Royalties. Payments of Royalties shall be made in cash to the
 extent such Royalties do not cause the Company&amp;#x2019;s cash as of
 the end of any year to be less than the Minimum Cash Balance, and
 otherwise shall be paid as Paid-In-Kind Royalties.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DebtInstrumentIssuanceDate1 contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_E83D7809-E371-49DE-9910-E4223A88D347_4_4">2006-05-16</us-gaap:DebtInstrumentIssuanceDate1>
  <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_EFBF7476-5E3F-4CEC-B0C4-FF96758A1AB8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;10. Derivative Instruments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Derivative instruments consist of the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;27,180&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,501&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;987&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,722&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,926&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2009 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,774&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;930&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated June 2010 MHR Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;282&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,248&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;654&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 August 2010 Investor Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated August 2010 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;464&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;243&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,432&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;750&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 July 2011 Investor Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;426&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Amended and Restated July 2011 MHR Waiver Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;378&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;198&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 May 2013 MHR Modification Warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,757&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,492&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;41,836&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,920&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: rgb(0,0,0) 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Some of the Company&amp;#x2019;s outstanding derivative instruments have
 an exercise price reset feature. The estimated fair value of
 warrants and embedded conversion features that have an exercise
 price reset feature is estimated using the Monte Carlo valuation
 model. The estimated fair value of warrants that do not contain an
 exercise price reset feature is measured using the Black-Scholes
 valuation model. Inherent in both of these models are assumptions
 related to expected volatility, remaining life, risk-free rate and
 expected dividend yield. For the Monte Carlo model, we estimate the
 probability and timing of potential future financing and
 fundamental transactions as applicable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;&lt;i&gt;Embedded Conversion Feature of MHR Notes.&lt;/i&gt;&lt;/b&gt;&amp;#xA0;The Convertible Notes, the
 Reimbursement Notes, and the Bridge Notes (collectively, the
 &amp;#x201C;MHR Notes&amp;#x201D;) contain a provision whereby the conversion
 price is adjustable upon the occurrence of certain events,
 including the issuance by Emisphere of common stock or common stock
 equivalents at a price which is lower than the current conversion
 price of each of the MHR Notes and lower than the then-current
 market price. Under FASB ASC 815-40-15-5, the embedded conversion
 feature of the MHR Notes is not considered indexed to the
 Company&amp;#x2019;s own stock and, therefore, does not meet the scope
 exception in FASB ASC 815-10-15 and thus needs to be accounted for
 as a derivative liability. The liabilities associated with the MHR
 Notes has been presented as a non-current liability as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, to correspond
 to their host contracts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Convertible Notes&lt;/b&gt;&lt;b&gt;&lt;i&gt;.&lt;/i&gt;&lt;/b&gt;&amp;#xA0;In addition to the foregoing,
 the adjustment provision of the Convertible Notes does not become
 effective unless and until the Company were to raise $10 million
 through the issuance of common stock or common stock equivalents
 during any consecutive 24 month period. The fair value of the
 embedded conversion feature of the Convertible Notes is estimated
 at the end of each quarterly reporting period using the Monte Carlo
 model. The assumptions used in computing the fair values as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the embedded conversion feature of the
 Convertible Notes decreased $0.3 million and increased $4.0 million
 for the three and nine months ended September&amp;#xA0;30, 2015,
 respectively, which has been recognized in the accompanying
 statements of operations. The fair value of the embedded conversion
 feature of the Convertible Notes increased $8.1 million and $10.7
 million for the three and nine months ended September&amp;#xA0;30,
 2014, respectively, which has been recognized in the accompanying
 statement of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Reimbursement Notes.&lt;/b&gt;&amp;#xA0;The fair value of the embedded
 conversion feature of the Reimbursement Notes is estimated at the
 end of each quarterly reporting period using the Monte Carlo model.
 The assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the embedded conversion of the Reimbursement
 Notes decreased $33 thousand and increased $0.2 million for the
 three and nine months ended September&amp;#xA0;30, 2015, respectively,
 which has been recognized in the accompanying statements of
 operations. The fair value of the embedded conversion feature of
 the Reimbursement Notes increased by $0.9 million and $0.9 million
 for the three and nine months ended September&amp;#xA0;30, 2014,
 respectively, which has been recognized in the accompanying
 statement of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Bridge Notes.&lt;/b&gt;&amp;#xA0;The fair value of the embedded
 conversion feature of the Bridge Notes is estimated at the end of
 each quarterly reporting period using the Monte Carlo model. The
 assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the embedded conversion feature of the Bridge
 Notes decreased $0.1 million and increased $0.6 million for the
 three and nine months ended September&amp;#xA0;30, 2015 respectively,
 which has been recognized in the accompanying statements of
 operations. The fair value of the embedded conversion feature of
 the Bridge Notes increased $0.6 million and $1.0 million for the
 three and nine months ended September&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Amended and Restated June 2010 Warrants.&lt;/b&gt;&amp;#xA0;In June 2010, the Company
 granted MHR warrants to purchase 865,000 shares of its common stock
 (the &amp;#x201C;June 2010 Warrants&amp;#x201D;). In connection with the
 Restructuring, on May&amp;#xA0;7, 2013, the Company amended and
 restated the Original Warrants such that the expiration date of the
 Original Warrant was extended to July&amp;#xA0;8, 2019, and the
 exercise price was reduced to $0.50 per share (as amended and
 restated, the &amp;#x201C;Amended and Restated June 2010
 Warrants&amp;#x201D;). The exercise price of the Amended and Restated
 June 2010 Warrants is adjustable upon the occurrence of certain
 events, including the issuance by Emisphere of common stock or
 common stock equivalents at a price which is lower than the current
 exercise price of these warrants and lower than the current market
 price. However, the adjustment provision does not become effective
 unless the Company were to raise $10 million through the issuance
 of common stock or common stock equivalents at a price which is
 lower than the current conversion price of these warrants and lower
 than the current market price during any consecutive 24 month
 period. The fair value of the Amended and Restated June 2010
 Warrants is estimated at the end of each quarterly reporting period
 using the Monte Carlo model. The assumptions used in computing the
 fair value of the Amended and Restated June 2010 Warrants as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the Amended and Restated September 2010 MHR
 Warrants decreased $60 thousand and increased $0.2 million for the
 three and nine months ended September&amp;#xA0;30, 2015, respectively,
 which has been recognized in the accompanying statements of
 operations. The fair value of the Amended and Restated September
 2010 MHR Warrants decreased $2 thousand and increased $102 thousand
 for the three and nine months September&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Amended and Restated Warrants.&lt;/b&gt;&amp;#xA0;Prior to the Restructuring,
 the Company issued to MHR warrants to purchase varying amounts of
 its common stocks at various times from 2009 through 2011, as
 described more fully below (the August 2009 Warrants, August 2010
 Warrants, August 2010 MHR Waiver Warrants, July 2011 Warrants, July
 2011 MHR Waiver Warrants, and collectively, the &amp;#x201C;Original
 Warrants&amp;#x201D;). In connection with the Restructuring, on
 May&amp;#xA0;7, 2013, the Company amended and restated each of the
 Original Warrants such that the expiration date of each Original
 Warrant was extended to July&amp;#xA0;8, 2019, and the exercise price
 was reduced to $0.50 per share (as amended and restated, the
 &amp;#x201C;Amended and Restated August 2009 Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated August 2010 Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated August 2010 MHR Waiver Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated July 2011 Warrants&amp;#x201D;,
 &amp;#x201C;Amended and Restated July 2011 MHR Waiver Warrants&amp;#x201D;,
 and collectively, the &amp;#x201C;Amended and Restated Warrants&amp;#x201D;).
 Under the terms of each of the Amended and Restated Warrants, as
 well as the August 2010 Investor Warrants, July 2011 Investor
 Warrants and 2013 Restructuring Warrants (collectively, the
 Investor Warrants, and together with the Original Warrants, the
 &amp;#x201C;Warrants&amp;#x201D;), the Company has an obligation to make a
 cash payment to the holders of each of the Warrants for any gain
 that could have been realized if such holder exercised the warrants
 and we subsequently failed to deliver a certificate representing
 the shares to be issued upon such exercise by the third trading day
 after the Warrants were exercised. Accordingly, the Warrants have
 been accounted for as a liability. The fair value of each of the
 Warrants is estimated, at the end of each quarterly reporting
 period, using the Black-Scholes model. The assumptions used in
 computing the fair value of the Original Warrants as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;161&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the Original Warrants decreased $1.0 million and
 increased $2.5 million for the three and nine months ended
 September&amp;#xA0;30, 2015, respectively, which has been recognized in
 the accompanying statements of operations. The fair value of the
 Original Warrants increased $0.5 million and $2.3 million for the
 three and nine months ended September&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;2013 Restructuring Warrants.&lt;/b&gt;&amp;#xA0;The Company issued to MHR
 warrants to purchase 10&amp;#xA0;million shares of its common stock
 (the &amp;#x201C;2013 Restructuring Warrants&amp;#x201D;) as part of the
 Restructuring. The assumptions used in computing the fair value of
 the 2013 Restructuring Warrants as of September&amp;#xA0;30, 2015 and
 December&amp;#xA0;31, 2014, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;161&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the 2013 Restructuring Warrants decreased $0.9
 million and increased $2.3 million for the three and nine months
 ended September&amp;#xA0;30, 2015, respectively, which has been
 recognized in the accompanying statements of operations. The fair
 value of the 2013 Restructuring Warrants increased $0.5 million and
 $1.9 million for the three and nine months ended September&amp;#xA0;30,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;August 2010 Investor Warrants.&lt;/b&gt;&amp;#xA0;In connection with the August
 2010 Financing, Emisphere sold warrants to purchase
 2.6&amp;#xA0;million shares of common stock to unrelated investors (the
 &amp;#x201C;August 2010 Warrants&amp;#x201D;). On January&amp;#xA0;12, 2011, one
 of the unrelated investors notified the Company of its intention to
 exercise 0.2&amp;#xA0;million warrants. In August 2015, the remaining
 August 2010 Warrants expired. The assumptions used in computing the
 fair value of the August 2010 Warrants as of December&amp;#xA0;31,
 2014, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the August 2010 Investor Warrants decreased $15
 thousand and $29 thousand for three and nine months ended
 September&amp;#xA0;30, 2015, respectively, which has been recognized in
 the accompanying statements of operations. The fair value of the
 August 2010 Investor Warrants decreased $43 thousand and $62
 thousand for the three and nine months ended September&amp;#xA0;30,
 2014.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;July 2011 Investor Warrants.&lt;/b&gt;&amp;#xA0;In connection with the July
 2011 Financing, Emisphere sold warrants to purchase
 3.01&amp;#xA0;million shares of common stock to unrelated investors
 (the &amp;#x201C;July 2011 Warrants&amp;#x201D;). The July 2011 Warrants are
 exercisable at $1.09 per share and have an expiration date of
 July&amp;#xA0;6, 2016. The assumptions used in computing the fair value
 of the July 2011 Warrants as of September&amp;#xA0;30, 2015 and
 December&amp;#xA0;31, 2014, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The fair value of the July 2011 Warrants decreased $0.2 million and
 increased $0.2 million for the three and nine months ended
 September&amp;#xA0;30, 2015, respectively, which has been recognized in
 the accompanying statements of operations. The July 2011 Warrants
 decreased $0.1 million and increased $0.1 million for the three and
 nine months ended September&amp;#xA0;30, 2014, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="INF" id="id_9160902_701523FA-32C2-4544-B593-B436AEBF5A78_1_3">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <dei:DocumentPeriodEndDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_56F9EA02-4353-4A2E-933F-BDECD0242E50_1_2">2015-09-30</dei:DocumentPeriodEndDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="INF" id="id_9160902_701523FA-32C2-4544-B593-B436AEBF5A78_2_4">0.0199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_CE6D1025-AB09-4084-A813-8B9815EA677A_2_3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_23E5D91D-D0C5-4717-A2C6-8175C4340284_1_2">Interest at a rate of 13% per annum (the "Interest Rate"), compounded monthly,  and will be payable in kind and in arrears on June 30 and December 31 of each  year</us-gaap:DebtInstrumentInterestRateTerms>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_8B15FF66-C702-4683-A0B7-2E73B5CCD1C8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. Stock-Based Compensation Plans&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On April&amp;#xA0;20, 2007, our stockholders approved the 2007 Stock
 Award and Incentive Plan (the &amp;#x201C;2007 Plan&amp;#x201D;). The 2007
 Plan provides for grants of options, stock appreciation rights,
 restricted stock, deferred stock, bonus stock and awards in lieu of
 obligations, dividend equivalents, other stock-based awards and
 performance awards to our executive officers and other employees,
 and non-employee directors, consultants and others who provide
 substantial services to us. The 2007 Plan provides for the issuance
 of an aggregate 9,195,376 shares as follows. As of
 September&amp;#xA0;30, 2015, 2,913,766 shares are available for future
 grants under all of our equity plans.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Total compensation expense recorded during the three and nine
 months ended September&amp;#xA0;30, 2015 for share-based payment awards
 was $89&amp;#xA0;thousand and $219 thousand, respectively. At
 September&amp;#xA0;30, 2015, total unrecognized estimated compensation
 expense related to non-vested stock options granted prior to that
 date was $0.6 million which is expected to be recognized over a
 weighted-average period of approximately 2.4 years. No options were
 exercised in the three or nine months ended September&amp;#xA0;30,
 2015. No tax benefit was realized due to a continued pattern of
 operating losses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 During the nine months ended September&amp;#xA0;30, 2015, the Company
 granted 1,570,000 options which included, 175,000 options to
 Timothy Rothwell, Chairman of the Board, 75,000 options to each of
 the Company&amp;#x2019;s other outside directors (valued on the grant
 date of March&amp;#xA0;3, 2015 at $0.55 using the Black Scholes pricing
 model); an additional 40,000 options to each of the Company&amp;#x2019;s
 outside directors (valued on the grant date of May&amp;#xA0;20, 2015,
 at $0.48); 300,000 options to Alan L. Rubino, President and Chief
 Executive Officer, 150,000 options to Carl Sailer, Vice President,
 Sales and Marketing, and 40,000 options to Michael Garone, Chief
 Financial Officer (valued on the grant date at $0.55 using the
 Black Scholes pricing model); and an additional 40,000 to Michael
 Garone, Chief Financial Officer (valued on the grant date at $0.34
 using the Black Scholes pricing model); and 250,000 options to
 non-executive employees and consultants (valued on the grant date
 at $0.59 using the Black Scholes pricing model).&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following weighted-average assumptions were used for grants
 made under the stock option plans for the nine months ended
 September&amp;#xA0;30, 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;145.87-148.95&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.58-1.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Annual forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.523&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_8B25A99B-8C99-4895-AA13-60730E01DD64_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In July 2015, the FASB issued ASU
 No.&amp;#xA0;2015-11,&amp;#xA0;&amp;#x201C;Simplifying the Measurement of
 Inventory&amp;#x201D; (&amp;#x201C;ASU 2015-11&amp;#x201D;). ASU 2015-11 requires
 that inventory within the scope of the guidance be measured at the
 lower of cost and net realizable value. Inventory measured using
 last-in, first-out (LIFO) and retail inventory method (RIM) are
 excluded from this new guidance. This ASU replaces the concept of
 market with the single measurement of net realizable value and is
 intended to create efficiencies for preparers and more closely
 aligns U.S. GAAP with IFRS. This ASU is effective for public
 business entities in fiscal years beginning after December&amp;#xA0;15,
 2016, including interim periods within those years. Prospective
 application is required and early adoption is permitted as of the
 beginning of an interim or annual reporting period. The Company is
 currently evaluating the impact of the new standards.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In April&amp;#xA0;2015, the FASB issued ASU 2015-03, &amp;#x201C;Interest
 &amp;#x2013; Imputation of Interest&amp;#x201D; (&amp;#x201C;ASU 2015-03&amp;#x201D;),
 which requires that debt issuance costs related to a recognized
 debt liability be presented in the balance sheet as a direct
 deduction from the carrying amount of that debt liability,
 consistent with debt discounts. The recognition and measurement
 guidance for debt issuance costs are not affected by the amendments
 in this ASU. ASU 2015-03 is effective for annual and interim
 periods beginning on or after December&amp;#xA0;15, 2015. The adoption
 of ASU 2015-03 is not expected to have a material impact on our
 financial position, results of operations or cash flows.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, &amp;#x201C;Revenue
 from Contracts with Customers&amp;#x201D; (&amp;#x201C;ASU 2014-09&amp;#x201D;),
 which requires entities to recognize revenue in a way that depicts
 the transfer of promised goods or services to customers in an
 amount that reflects the consideration to which the entity expects
 to be entitled to in exchange for those goods or services. The new
 guidance also requires additional disclosure about the nature,
 amount, timing and uncertainty of revenue and cash flows arising
 from customer contracts, including significant judgments and
 changes in judgments and assets recognized from costs incurred to
 obtain or fulfill a contract. In July 2015, the FASB voted to delay
 the effective date of ASU 2014-09 by one year to the first quarter
 of 2018 to provide companies sufficient time to implement the
 standards. Early adoption will be permitted, but not before the
 first quarter of 2017. Adoption can occur using one of two
 prescribed transition methods. The Company is currently evaluating
 the impact of the new standard.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15,
 &amp;#x201C;Disclosure of Uncertainties About an Entity&amp;#x2019;s Ability
 to Continue as a Going Concern&amp;#x201D; (&amp;#x201C;ASU 2014-15&amp;#x201D;),
 which provides guidance on management&amp;#x2019;s responsibility in
 evaluating whether there is substantial doubt about an
 entity&amp;#x2019;s ability to continue as a going concern and to
 provide related footnote disclosures. ASU 2014-15 is effective for
 the annual period ending after December&amp;#xA0;15, 2016, and for
 annual and interim periods thereafter. The adoption of ASU 2014-15
 is not expected to have a material impact on our financial
 position, results of operations or cash flows.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_54BD5FFA-E8B6-43B6-800A-4752F9D3737B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As of September&amp;#xA0;30, 2015, future minimum rental payments are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-BOTTOM: #000000 1pt solid; WIDTH: 95.55pt"&gt;
 &lt;b&gt;Years Ending December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(In&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2015 (remaining)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;31&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;74&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;253&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <dei:TradingSymbol contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_46C9DFF1-11EF-4B62-A749-FDE81E2D8BE5_1_0">EMIS</dei:TradingSymbol>
  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_CED798BF-52B6-4963-A3E1-4E3419E22F3F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Notes payable, net of related discounts, consists of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Second Amended and Restated Convertible Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;36,497&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;35,332&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Loan Agreement&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Second Amended and Restated Bridge Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;191&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;271&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Second Amended and Restated Reimbursement Notes&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;636&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Non-current notes payable, net of related discounts&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58,669&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,546&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="INF" id="id_9160902_701523FA-32C2-4544-B593-B436AEBF5A78_1_0">1.4587</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="shares" decimals="0" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_D87E3D9A-EDF6-4F02-ACCE-0379A8C0FF51_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following weighted-average assumptions were used for grants
 made under the stock option plans for the nine months ended
 September&amp;#xA0;30, 2015:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="81%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;145.87-148.95&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.58-1.99&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Annual forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.523&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_1_0">1570000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_0DCBEA34-17E3-4E3D-A231-6484A02988B4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;15. Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 During October, 2015, we entered into a Development and License
 Agreement with Novo Nordisk (the &amp;#x201C;Expansion License
 Agreement&amp;#x201D;) to develop and commercialize oral formulations of
 four classes of Novo Nordisk&amp;#x2019;s investigational molecules
 targeting major metabolic disorders, including diabetes and
 obesity, using our oral Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology. Under the terms of
 the Expansion License Agreement, we licensed to Novo Nordisk the
 exclusive right to develop potential product candidates in three
 molecule classes, and the non-exclusive right to develop potential
 product candidates in a fourth molecule class, using the
 Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology. Pursuant to the
 Expansion License Agreement, we received a $5.0 million upfront
 licensing fee, and are eligible to receive up to $62.5 million in
 development and sales milestone payments for each of the three
 exclusively licensed molecule classes, and up to $20 million in
 development milestone payments for the non-exclusively licensed
 molecule class. Additionally, we are eligible to receive royalties
 on sales of each successfully commercialized product. Novo Nordisk
 is solely responsible for the development and commercialization of
 all product candidates. In addition, we granted Novo Nordisk the
 option to obtain exclusive and non-exclusive rights to develop and
 commercialize oral formulations of additional investigational
 molecules for the treatment of diabetes, obesity, and indications
 in other therapeutic areas using the Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology. If Novo Nordisk
 exercises its option to develop and commercialize any additional
 investigational molecules, we would be eligible to receive an
 additional payment upon the exercise of each option for exclusive
 or non-exclusive development rights for each molecule class. We are
 eligible to receive up to $62.5 million in development and sales
 milestone payments for each additional exclusively licensed
 molecule class, and up to $20 million in development milestone
 payments for each additional non-exclusively licensed molecule
 class, plus royalties on sales of each commercialized product. The
 agreement remains in effect, on a country-by-country basis, for the
 longer of 10 years from the date of first sale of a licensed
 product in such country, or the date of expiration of the
 last-to-expire patent covered by the agreement in such country.
 Novo Nordisk may terminate this agreement with 90 days prior
 notice. We may terminate this agreement in the event that Novo
 Nordisk challenges the validity of any licensed patent under the
 agreement, but only with respect to the patents belonging to the
 patent family of the challenged patent. Either party may also
 terminate the agreement upon the other party&amp;#x2019;s material
 breach, if not cured within a specified period of time. Upon a
 termination of the agreement by Emisphere for Novo Nordisk&amp;#x2019;s
 breach, all intellectual property rights conveyed under the
 agreement shall revert back to us.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Coincident with the Expansion License Agreement, we amended the
 GLP-1 License Agreement with Novo Nordisk to provide for, among
 other things, a payment of $9.0 million to us from Novo Nordisk as
 prepayment of a product development milestone in exchange for a
 reduction in certain future royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On November&amp;#xA0;10, 2015, the creditor under our Loan Agreement
 and Convertible Notes agreed to waive any event of default
 resulting from our failure to satisfy the net sales milestones for
 the Eligen&amp;#xA0;B12&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#x2122;&lt;/sup&gt;&amp;#xA0;product for the 2015 fiscal
 year specified in our Loan Agreement and Convertible Notes.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_18">-30254000</us-gaap:NetIncomeLoss>
  <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="INF" id="id_9160902_CE6D1025-AB09-4084-A813-8B9815EA677A_2_4">0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions>
  <us-gaap:Revenues contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_0">225000</us-gaap:Revenues>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_10">535000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_26">3928000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_8">-13900000</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInInventories contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_9">-14000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:GrossProfit contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_2">87000</us-gaap:GrossProfit>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_10">8000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_15">-16354000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_8">305000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:UnrealizedGainLossOnDerivatives contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_4">-9971000</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_16">-30254000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_13">-188000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_6">219000</us-gaap:ShareBasedCompensation>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_12">382000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_14">6391000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_22">-2279000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_7">13987000</us-gaap:OperatingExpenses>
  <us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_16">2000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_21">12000000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_4">382000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RoyaltyExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_6A829ECE-293E-4EC9-83E2-646DF4A3AD9F_1_0">121000</us-gaap:RoyaltyExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_14">-174000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_CE6D1025-AB09-4084-A813-8B9815EA677A_2_0">219000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_5">13595000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_17">15975000</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_6">10000</us-gaap:DepreciationAndAmortization>
  <us-gaap:IncreaseDecreaseInRoyaltiesPayable contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_13">121000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
  <us-gaap:ProceedsFromLoans contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_20">12000000</us-gaap:ProceedsFromLoans>
  <us-gaap:Depreciation contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_3">10000</us-gaap:Depreciation>
  <us-gaap:CostOfRevenue contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_1">138000</us-gaap:CostOfRevenue>
  <emis:AdjustedFreeCashFlowIncome contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-6" id="id_9160902_6868E01D-D1E3-4DA0-9715-A109A57C82E9_1_2">50000000</emis:AdjustedFreeCashFlowIncome>
  <emis:OperatingLeaseExpirationPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_CF82CA43-39D0-438A-BA94-1CE0B6EFF991_1_0">2017</emis:OperatingLeaseExpirationPeriod>
  <emis:NatureOfOperationsAndLiquidityTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_DA07A48B-563E-49BA-B8F7-052880229ABD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;1. Nature of Operations and Liquidity&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Nature of Operations&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Emisphere Technologies, Inc. (&amp;#x201C;Emisphere,&amp;#x201D; &amp;#x201C;the
 Company,&amp;#x201D; &amp;#x201C;our,&amp;#x201D; &amp;#x201C;us,&amp;#x201D; or
 &amp;#x201C;we&amp;#x201D;) is a commercial stage pharmaceutical and drug
 delivery company that has recently commenced commercial operations.
 We launched our first prescription medical food product, oral
 Eligen B12&amp;#x2122; (1000 mcg.), in the U.S. in March 2015, and is in
 partnership with global pharmaceutical companies to develop new
 formulations of existing products, as well as new chemical
 entities, using our Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology. Additionally, we
 are currently engaged in multiple ex-US licensing discussions with
 the intention of offering oral Eligen B12&amp;#x2122; for sale in global
 markets. Beyond Eligen B12&amp;#x2122;, we utilize our proprietary
 Eligen&amp;#xA0;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology to create new oral
 formulations of therapeutic agents. Our product pipeline includes
 prescription drug and medical food product candidates that are
 being developed in partnership or internally.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 By building on the oral Eligen B12&amp;#x2122; product, we intend to
 establish a sound product portfolio platform on which to expand the
 B12 therapeutic franchise as well as expand internal new product
 development with new therapeutic agents. We will also continue to
 develop our existing drug delivery carrier partnerships and expand
 our carrier business by seeking out and engaging in new global
 licensing opportunities.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Our core business strategy is to pursue the commercialization of
 oral Eligen B12&amp;#x2122; , build new, high-value partnerships and
 continue to expand upon existing partnerships, evaluate commercial
 opportunities for new prescription medical foods, and promote new
 uses for our Eligen&amp;#xA0;&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;Technology, a
 broad-based proprietary oral drug delivery platform which makes it
 possible to avoid injections for drug administration through the
 use of delivery agents, or &amp;#x201C;carriers,&amp;#x201D; which facilitate
 or enable transport of therapeutic molecules, including large
 peptides and proteins, across biological membranes such as those of
 the gastrointestinal tract. Our delivery agents have no known
 pharmacological activity in the amounts used to enhance drug
 delivery and therefore may be considered excipients.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Liquidity and Capital Resources&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Since our inception in 1986, we have generated significant losses
 from operations and we anticipate that we will continue to generate
 significant losses from operations for the foreseeable future, and
 that in order to continue as a going concern, our business will
 require substantial additional investment that we have not yet
 secured.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 As of September&amp;#xA0;30, 2015, our accumulated deficit was
 approximately $544.4&amp;#xA0;million; our stockholder&amp;#x2019;s deficit
 was $142.0 million. The net loss was $4.4 million compared to a net
 loss of $14.4 million for the three months ended September&amp;#xA0;30,
 2015 and 2014, respectively; the net loss was $30.3 million and
 $25.8 million for the nine months ended September&amp;#xA0;30, 2015 and
 2014, respectively. On September&amp;#xA0;30, 2015 we had approximately
 $1.4 million cash. We have limited capital resources and operations
 to date have been funded with the proceeds from private and public
 debt and equity financings, collaborative research agreements and
 income earned on investments.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 As of September&amp;#xA0;30, 2015, our financial obligations included
 approximately $43.6 million (face value) under our Second Amended
 and Restated Convertible Notes (the &amp;#x201C;Convertible
 Notes&amp;#x201D;), approximately $21.3 million (face value) under a
 loan agreement entered into on August&amp;#xA0;20, 2014 (the
 &amp;#x201C;Loan Agreement&amp;#x201D;), approximately $0.7 million (face
 value) under our Second Amended and Restated Reimbursement Notes
 (the &amp;#x201C;Reimbursement Notes&amp;#x201D;), and approximately $2.0
 million (face value) under our Second Amended and Restated Bridge
 Notes (the &amp;#x201C;Bridge Notes&amp;#x201D;). The Convertible Notes and
 the Loan Agreement are subject to annual net sales performance
 targets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 Under the terms of the Loan Agreement, described in Note 9 to the
 Financial Statements, Emisphere borrowed an aggregate of $20.0
 million to finance the development, manufacturing, marketing and
 sales of its oral Eligen B12&amp;#x2122; Rx Product. The loan facility
 will mature on December&amp;#xA0;31, 2019 and bears interest at a rate
 of 13%&amp;#xA0;per year. The first borrowing under the Loan Agreement
 occurred on August&amp;#xA0;20, 2014, in an original principal amount
 of $5.0 million, the second occurred on November&amp;#xA0;4, 2014 in an
 original principal amount of $3.0 million, the third occurred on
 January&amp;#xA0;6, 2015 in an original principal amount of $5.0
 million, the fourth occurred on April&amp;#xA0;6, 2015 in an original
 principal amount of $5.0 million, and the fifth and final borrowing
 occurred on July&amp;#xA0;1, 2015 in an original principal amount of
 $2.0 million. In the event that we do not satisfy annual net sales
 targets of Eligen B12&amp;#x2122; by December&amp;#xA0;31 for each fiscal
 year beginning 2015 through 2019, we will be in default under the
 Loan Agreement, provided that we are not granted a waiver of the
 event of default resulting from the failure to satisfy the net
 sales target for the applicable year. On November&amp;#xA0;10, 2015,
 the creditor under our Loan Agreement and Convertible Notes agreed
 to waive any event of default resulting from our failure to satisfy
 the net sales milestones for the Eligen&amp;#xA0;B12&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#x2122;&lt;/sup&gt;&amp;#xA0;product for the 2015 fiscal
 year specified in our Loan Agreement and Convertible Notes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 On October&amp;#xA0;26, we received a total payment of $14 million from
 Novo Nordisk pursuant to, and consisting of, $5 million as payment
 for entry into the Expansion License Agreement and $9 million as
 payment in connection with the third amendment to the GLP-1 License
 Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 We believe our current cash balance, assuming attainment of sales
 and profitability targets for the oral Eligen B12&amp;#x2122; product,
 will provide sufficient capital to continue operations through
 approximately July 2016. Our future capital requirements beyond
 July 2016 and financial success depend largely on the commercial
 success of our oral Eligen B12&amp;#x2122; product and our ability to
 leverage existing and secure new partnering opportunities. There is
 no assurance that our plans will be successful. If we fail to
 generate sufficient capital from commercial operations or
 partnerships, we will need to seek capital from other sources and
 risk default under the terms of our existing loans. We cannot
 assure you that additional financing will be available on favorable
 terms or at all. If we fail to generate sufficient additional
 capital from sales of oral Eligen B12&amp;#x2122; or obtain substantial
 cash inflows from existing or new partners or other sources prior
 to approximately July 2016, we could be forced to cease operations.
 Additionally, if additional capital is raised through the sale of
 equity or convertible debt securities, the issuance of these
 securities will result in dilution to our existing stockholders.
 These conditions raise substantial doubt about our ability to
 continue as a going concern. Consequently, the audit reports
 prepared by our independent registered public accounting firm
 relating to our financial statements for&amp;#xA0;the years ended
 December&amp;#xA0;31, 2014, 2013 and 2012 include an explanatory
 paragraph expressing substantial doubt about our ability to
 continue as a going concern. Furthermore, despite our optimism
 regarding the Eligen&lt;sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top"&gt;&amp;#xAE;&lt;/sup&gt;&amp;#xA0;Technology, even in the event
 that we are adequately funded, there is no guarantee that any of
 our products or product candidates will perform as hoped or that
 these products will be successfully commercialized.&lt;/p&gt;
 &lt;/div&gt;</emis:NatureOfOperationsAndLiquidityTextBlock>
  <emis:MinimumPercentageOfCommonStockOutstandingToProvideContinuityToNomineeOnBoard contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="INF" id="id_9160902_E36CF798-3986-4A66-A664-4E89FF67CD26_1_1">0.02</emis:MinimumPercentageOfCommonStockOutstandingToProvideContinuityToNomineeOnBoard>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="2" id="id_9160902_3B9DEB91-F038-4463-8B01-44DA6D086D5C_1_2">0.75</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <emis:CashSweepAsPercentageOfCashProceeds contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="2" id="id_9160902_6868E01D-D1E3-4DA0-9715-A109A57C82E9_1_3">0.50</emis:CashSweepAsPercentageOfCashProceeds>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlowUponConditions contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="2" id="id_9160902_6868E01D-D1E3-4DA0-9715-A109A57C82E9_1_1">0.75</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlowUponConditions>
  <emis:ShelfLifeOfProducts contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_8D2B92B3-3A91-4601-AE4F-26AC61D7B39F_3_1">P24M</emis:ShelfLifeOfProducts>
  <emis:RevenueRecognitionDisclosureTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_3FDD00F7-770D-48CE-A736-2F3CE8344B4F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;3. Revenue Recognition for the Company&amp;#x2019;s Oral Eligen
 B12&amp;#x2122; Rx Product&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 We recognize revenue in accordance with FASB ASC 605-10-S99,
 &lt;i&gt;Revenue Recognition.&lt;/i&gt; We sell our oral Eligen B12&amp;#x2122; Rx
 product through drug wholesalers and retail pharmacies. We
 recognize revenue from prescription product sales, net of sales
 discounts, chargebacks, and rebates. We accept returns of unsalable
 product from customers within a return period of six months prior
 to and 12 months following product expiration. Our oral Eligen
 B12&amp;#x2122; Rx product currently has a shelf life of 24 months from
 the date of manufacture. Given the limited history of our Oral
 Eligen B12&amp;#x2122; Rx product, we currently cannot reliably estimate
 expected returns of the product at the time of shipment.
 Accordingly, we defer recognition of revenue on prescription
 products until the right of return no longer exists, which occurs
 at the earlier of the time the oral Eligen B12&amp;#x2122; Rx product is
 dispensed through patient prescriptions or expiration of the right
 of return.&lt;/p&gt;
 &lt;/div&gt;</emis:RevenueRecognitionDisclosureTextBlock>
  <emis:StockAwardPlanAndIncentivePlanApprovalDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_4670FA74-3362-4313-BAAB-152BEE4B0ED2_1_0">2007-04-20</emis:StockAwardPlanAndIncentivePlanApprovalDate>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="pure" decimals="5" id="id_9160902_701523FA-32C2-4544-B593-B436AEBF5A78_3_6">0.14523</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate>
  <emis:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" id="id_9160902_906C9BE1-EE1A-46AC-BF4C-D5273F70358C_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;6. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid expenses and other current assets consist of the
 following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;br /&gt;
 (unaudited)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid corporate insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;37&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;53&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Deposit on inventory&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;184&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;501&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;135&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;722&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;188&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</emis:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <emis:NoncashInterestExpense contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_5">6270000</emis:NoncashInterestExpense>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_1_12">0.59</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare>
  <emis:IncreaseInDebtDiscountForNewDerivatives contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_8765D6C2-CE36-4513-AAF8-9D5ABF834C7C_1_27">1945000</emis:IncreaseInDebtDiscountForNewDerivatives>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_3_12">-9783000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1633944x1965446_1635457x1637088_1640267x1946637" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_1001_6">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1633944x1965446_1635457x1641124_1640267x1946637" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_2001_8">0.55</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1633944x1965447_1635457x1641124_1640267x1946637" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_3001_9">40000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1633944x1965447_1635457x1641124_1640267x1946637" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_3001_10">0.34</emis:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValuePerShare>
  <emis:PropertyPlantAndEquipmentLife contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1634505x1633425" id="id_9160902_4CE32C09-8CA9-4BEA-BBA1-0736D53FF17F_1003_1">Term of lease</emis:PropertyPlantAndEquipmentLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1634505x1638371_1639304x1633605" id="id_9160902_4CE32C09-8CA9-4BEA-BBA1-0736D53FF17F_2002_0">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1634505x1638371_1639304x1643741" id="id_9160902_4CE32C09-8CA9-4BEA-BBA1-0736D53FF17F_2001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1634496" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_4001_4">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1637088" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_5001_5">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1639460" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_6001_1">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1846485" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_8001_2">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1976750" unitRef="shares" decimals="INF" id="id_9160902_3BA4636F-7524-4167-97F0-9341EFF8ACFA_9001_11">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1637754" unitRef="pure" decimals="2" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1001_2">1.44</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1637754" unitRef="pure" decimals="4" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1001_4">0.0092</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1637754" id="id_9160902_68D67A80-D695-4A5E-8866-DB7D4D9C609B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value of the Original
 Warrants as of September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014,
 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;161&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1637754" unitRef="pure" decimals="2" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1637754" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60EADD80-ABFF-40AB-9C13-AB0DD87F361A_1002_0">2500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1637754" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1001_3">P3Y9M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732474" unitRef="pure" decimals="2" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1001_2">1.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732474" unitRef="pure" decimals="4" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1001_4">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732474" id="id_9160902_AEC1B20E-2558-4DC0-955A-22ED123DEBAC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 The assumptions used in computing the fair values as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 12pt &apos;Times New Roman&apos;; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: &apos;Times New Roman&apos;; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732474" unitRef="pure" decimals="2" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732474" unitRef="iso4217_USD" decimals="-5" id="id_9160902_70C83B15-F7C0-4D14-8F49-4D169AEA98F4_1002_0">4000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732474" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1001_3">P6Y6M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732774" unitRef="pure" decimals="2" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1001_2">1.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732774" unitRef="pure" decimals="4" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1001_4">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732774" id="id_9160902_13B3F00D-9F3E-4045-97AE-723FDA0FECB7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732774" unitRef="pure" decimals="2" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732774" unitRef="iso4217_USD" decimals="-5" id="id_9160902_869A1765-D840-4EA2-8C93-07661187CDB7_1002_500001">200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732774" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1001_3">P6Y6M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1737996" unitRef="pure" decimals="2" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1001_2">1.31</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1737996" unitRef="pure" decimals="4" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1001_4">0.0033</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1737996" id="id_9160902_58AF87ED-B97A-405C-BE73-BCA382F7755D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 The assumptions used in computing the fair value of the July 2011
 Warrants as of September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014,
 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;131&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;122&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.33&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;.67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1737996" unitRef="pure" decimals="2" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1737996" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1001_3">P9M4D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" unitRef="pure" decimals="2" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1001_2">1.44</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" unitRef="pure" decimals="4" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1001_4">0.0109</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" id="id_9160902_58DBED96-A3E2-4B6F-9641-C7EBFAAE8C07_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value of the Amended and
 Restated June 2010 Warrants as of
 September 30, 2015 and December&amp;#xA0;31, 2014, are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;160&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.09&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.51&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" unitRef="pure" decimals="2" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" unitRef="iso4217_USD" decimals="-5" id="id_9160902_5D88D9BA-E3CD-4799-890D-94F2D2BD63B5_1002_1">200000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:ReducedExercisePriceOfWarrants contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_EB988641-BC7E-46DC-B7AB-0ED423EBFBCC_1001_2">0.50</emis:ReducedExercisePriceOfWarrants>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1001_3">P3Y9M7D</emis:RemainingTermOfExpectedVolatility>
  <emis:WarrantsExpiryDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496" id="id_9160902_EB988641-BC7E-46DC-B7AB-0ED423EBFBCC_1001_3">2019-07-08</emis:WarrantsExpiryDate>
  <emis:FairValueOfWarrantsIncreased contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1824912" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60DCB710-7769-4813-9F68-1337611475B5_1002_0">200000</emis:FairValueOfWarrantsIncreased>
  <emis:WarrantsExpiryDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1824912" id="id_9160902_4F179EC8-8748-4301-808B-25E42FFBA719_1_2">2016-07-06</emis:WarrantsExpiryDate>
  <emis:NumberOfWarrantsSoldToFund contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1824912" unitRef="shares" decimals="-4" id="id_9160902_4F179EC8-8748-4301-808B-25E42FFBA719_1_0">3010000</emis:NumberOfWarrantsSoldToFund>
  <emis:ExercisePriceOfWarrantsIssued contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1824912" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_4F179EC8-8748-4301-808B-25E42FFBA719_1_1">1.09</emis:ExercisePriceOfWarrantsIssued>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1920444" id="id_9160902_935B6721-257E-4BEF-80E4-4930CDC2666A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value of the August 2010
 Warrants as of December&amp;#xA0;31, 2014, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="87%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;116&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;.12&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1920444" unitRef="iso4217_USD" decimals="-3" id="id_9160902_520B2E6E-3AD8-41FE-8B06-98CCE3472547_1002_1">29000</emis:FairValueOfWarrantsDecreased>
  <emis:WarrantsExpiryDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1920444" id="id_9160902_8C4EFE81-A58E-4BF5-833A-4E50D18628C6_1001_2">2015-08-31</emis:WarrantsExpiryDate>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1921945" unitRef="pure" decimals="2" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1001_2">1.44</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1921945" unitRef="pure" decimals="4" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1001_4">0.0092</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1921945" id="id_9160902_E0BF111E-55B1-4E39-883F-71AB1760D6D7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value of the 2013
 Restructuring Warrants as of September&amp;#xA0;30, 2015 and
 December&amp;#xA0;31, 2014, are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;161&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.77&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.92&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.65&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1921945" unitRef="pure" decimals="2" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:FairValueOfWarrantsIncreased contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1921945" unitRef="iso4217_USD" decimals="-5" id="id_9160902_6EDA1CFC-F930-43C6-A1C1-AEC2D7DEFA8D_1002_1">2300000</emis:FairValueOfWarrantsIncreased>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1921945" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1001_3">P3Y9M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1936828" unitRef="pure" decimals="2" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1001_2">1.50</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1936828" unitRef="pure" decimals="4" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1001_4">0.0164</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1936828" id="id_9160902_819177DF-B15B-48C5-B287-2D15176F146F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The assumptions used in computing the fair value as of
 September&amp;#xA0;30, 2015 and December&amp;#xA0;31, 2014 are as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2014&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Closing stock price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.56&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.28&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Conversion price&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;140&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Remaining term (years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.25&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.64&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1936828" unitRef="pure" decimals="2" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1936828" unitRef="iso4217_USD" decimals="-5" id="id_9160902_5FEBBCEF-C0E2-4062-B1A3-60C51857BE2A_1002_0">600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1936828" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1001_3">P6Y6M</emis:RemainingTermOfExpectedVolatility>
  <emis:PeriodOfProductReturnAfterExpiration contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1639304x1633605" id="id_9160902_8D2B92B3-3A91-4601-AE4F-26AC61D7B39F_2_0">P12M</emis:PeriodOfProductReturnAfterExpiration>
  <emis:PeriodOfProductReturnAfterExpiration contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1639304x1643741" id="id_9160902_8D2B92B3-3A91-4601-AE4F-26AC61D7B39F_1_0">P6M</emis:PeriodOfProductReturnAfterExpiration>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1691094" id="id_9160902_EEFA6D13-0D51-471F-9178-8BF32753C5CE_1001_1">2013-05-07</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <emis:DebtInstrumentAdditionalInterestRateStatedPercentageRate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1691094" unitRef="pure" decimals="INF" id="id_9160902_23E5D91D-D0C5-4717-A2C6-8175C4340284_1001_1">0.02</emis:DebtInstrumentAdditionalInterestRateStatedPercentageRate>
  <us-gaap:RestructuringAndRelatedActivitiesInitiationDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1732774" id="id_9160902_EEFA6D13-0D51-471F-9178-8BF32753C5CE_2001_2">2014-08-20</us-gaap:RestructuringAndRelatedActivitiesInitiationDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1732774" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_1001_0">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1732774" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_1001_2">Interest at the rate of 10% per annum, compounded monthly,  which interest is payable in the form of additional Reimbursement Notes.</us-gaap:DebtInstrumentInterestRateTerms>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1732774" unitRef="pure" decimals="2" id="id_9160902_59DFA1F0-0179-4EA3-A437-F150F177B0BD_1001_4">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1741680" id="id_9160902_F9EAE36F-D051-49F4-9D78-016149F87AE3_1001_1">2019-12-31</us-gaap:DebtInstrumentMaturityDate>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1741680" unitRef="pure" decimals="2" id="id_9160902_6868E01D-D1E3-4DA0-9715-A109A57C82E9_1001_0">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1936828" id="id_9160902_37052F73-EA57-493C-908C-971C28CBD10E_1001_0">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1936828" id="id_9160902_51B24575-9186-41D6-93FB-01EE24397EA3_1002_2">The Bridge Notes were amended and restated on May 7, 2013 and restated  again on August 20, 2014.</us-gaap:DefaultLongtermDebtDescriptionOfViolationOrEventOfDefault>
  <us-gaap:DebtInstrumentInterestRateTerms contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1936828" id="id_9160902_37052F73-EA57-493C-908C-971C28CBD10E_1001_2">Interest at 13% per year, compounded monthly and payable in the form of  additional Bridge Notes.</us-gaap:DebtInstrumentInterestRateTerms>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1936828" unitRef="pure" decimals="2" id="id_9160902_37052F73-EA57-493C-908C-971C28CBD10E_1001_3">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <emis:DebtInstrumentConvertibleAmendedConversionPrice contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1936828" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_9160902_37052F73-EA57-493C-908C-971C28CBD10E_1001_4">0.50</emis:DebtInstrumentConvertibleAmendedConversionPrice>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643973x1732474" unitRef="shares" decimals="INF" id="id_9160902_E38E4A31-CBE4-44AE-AF89-766EF527C12D_1001_4">34902557</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtInstrumentMaturityDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643973x1732474" id="id_9160902_3B9DEB91-F038-4463-8B01-44DA6D086D5C_1001_0">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
  <emis:AdjustedFreeCashFlowIncome contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643973x1732474" unitRef="iso4217_USD" decimals="-6" id="id_9160902_3B9DEB91-F038-4463-8B01-44DA6D086D5C_1001_3">50000000</emis:AdjustedFreeCashFlowIncome>
  <emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643973x1732474" unitRef="pure" decimals="2" id="id_9160902_3B9DEB91-F038-4463-8B01-44DA6D086D5C_1001_1">0.50</emis:CashSweepAsPercentageOfConsolidatedFreeCashFlow>
  <emis:CashSweepAsPercentageOfCashProceeds contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643973x1732474" unitRef="pure" decimals="2" id="id_9160902_E38E4A31-CBE4-44AE-AF89-766EF527C12D_1001_1">0.50</emis:CashSweepAsPercentageOfCashProceeds>
  <emis:RoyaltyAgreementDate contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643986x1636114" id="id_9160902_F27A6CDB-FD76-4072-98A1-AF04E024DF44_1001_0">2014-08-20</emis:RoyaltyAgreementDate>
  <emis:RoyaltyTermDescription contextRef="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643986x1636114" id="id_9160902_AF009F3E-26BE-49C6-9051-7A343D8A2A8F_1001_3">(i) five percent (5%) of all Net Sales and third party payments commencing with the first quarter immediately following the quarter in which the Indebtedness Repayment Condition is satisfied, or (ii) two and one half percent (2.5%) of all Net Sales commencing with the quarter immediately following the quarter in which the Indebtedness Repayment Condition is satisfied, but only with respect to the Net Sales made in any country in which there was not a Valid Patent Claim (as defined in the Royalty Agreement) and where generic entry of a competitive product not by the Company or its affiliates that does not infringe a Valid Patent Claim in such country has occurred, in each case as of the last day of such Fiscal Quarter.</emis:RoyaltyTermDescription>
  <emis:LicenseAgreementTerminationPeriod contextRef="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766" id="id_9160902_DD969184-CCFF-4555-9B20-509EC0A38BF7_1001_0">P90D</emis:LicenseAgreementTerminationPeriod>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997522" unitRef="iso4217_USD" decimals="INF" id="id_9160902_BF487D0E-F800-4971-AF09-CF01E41127B1_1001_2">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997523" unitRef="iso4217_USD" decimals="INF" id="id_9160902_BF487D0E-F800-4971-AF09-CF01E41127B1_2001_1">62500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997524" unitRef="iso4217_USD" decimals="INF" id="id_9160902_39A97D00-B25A-4F8B-BDF3-6FFCA6A56929_1001_0">62500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997525" unitRef="iso4217_USD" decimals="INF" id="id_9160902_39A97D00-B25A-4F8B-BDF3-6FFCA6A56929_2001_1">20000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1643986x1643540" unitRef="iso4217_USD" decimals="-5" id="id_9160902_BF487D0E-F800-4971-AF09-CF01E41127B1_3001_0">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:ProceedsFromCollaborators contextRef="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x2002476_1636141x1633766" unitRef="iso4217_USD" decimals="-5" id="id_9160902_26ADFD46-64E5-42FA-A86D-FAA43019C6A0_1001_0">9000000</us-gaap:ProceedsFromCollaborators>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_DEA79568-9E1A-41B2-8C1B-07A8D62E6156_2_4">10287000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1637754" unitRef="pure" decimals="2" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1002_2">1.61</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1637754" unitRef="pure" decimals="4" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1002_4">0.0165</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1637754" unitRef="pure" decimals="2" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1637754" id="id_9160902_DDCE2F53-A23A-4FF2-9527-E61EDD751B0C_1002_3">P4Y6M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732474" unitRef="pure" decimals="2" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1002_2">1.40</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732474" unitRef="pure" decimals="4" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1002_4">0.0197</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732474" unitRef="pure" decimals="2" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732474" id="id_9160902_FDBCFE27-F393-4EA6-B410-7DF301EC389F_1002_3">P7Y3M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732774" unitRef="pure" decimals="2" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1002_2">1.40</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732774" unitRef="pure" decimals="4" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1002_4">0.0197</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732774" unitRef="pure" decimals="2" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732774" id="id_9160902_86CB6FB7-AFA4-4CFB-8CE3-B6BB96741C5F_1002_3">P7Y3M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1737996" unitRef="pure" decimals="2" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1002_2">1.22</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1737996" unitRef="pure" decimals="4" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1002_4">0.0067</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1737996" unitRef="pure" decimals="2" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1737996" id="id_9160902_7C4F0481-DF2A-4E8D-A582-9C46DE4ED458_1002_3">P1Y6M4D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1802496" unitRef="pure" decimals="2" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1002_2">1.60</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1802496" unitRef="pure" decimals="4" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1002_4">0.0151</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1802496" unitRef="pure" decimals="2" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1802496" id="id_9160902_0599256F-0879-4B9B-A1F9-8586D1BC1CB9_1002_3">P4Y6M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1920444" unitRef="pure" decimals="2" id="id_9160902_03E7633C-B5D0-49F2-ABE9-48BE6B27B15D_1001_2">1.16</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1920444" unitRef="pure" decimals="4" id="id_9160902_03E7633C-B5D0-49F2-ABE9-48BE6B27B15D_1001_4">0.0012</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1920444" unitRef="pure" decimals="2" id="id_9160902_03E7633C-B5D0-49F2-ABE9-48BE6B27B15D_1001_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1920444" id="id_9160902_03E7633C-B5D0-49F2-ABE9-48BE6B27B15D_1001_3">P7M24D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1921945" unitRef="pure" decimals="2" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1002_2">1.61</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1921945" unitRef="pure" decimals="4" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1002_4">0.0165</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1921945" unitRef="pure" decimals="2" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1921945" id="id_9160902_22FD2F5A-6651-4AE4-9702-CE76C28763CA_1002_3">P4Y6M7D</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1936828" unitRef="pure" decimals="2" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1002_2">1.40</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1936828" unitRef="pure" decimals="4" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1002_4">0.0197</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1936828" unitRef="pure" decimals="2" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1002_5">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
  <emis:RemainingTermOfExpectedVolatility contextRef="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1936828" id="id_9160902_D5138DAD-F284-4916-A6FF-34D4D964D575_1002_3">P7Y3M</emis:RemainingTermOfExpectedVolatility>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_19">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="shares" decimals="INF" id="id_9160902_CE6D1025-AB09-4084-A813-8B9815EA677A_1_3">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="shares" decimals="0" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" id="id_9160902_CE6D1025-AB09-4084-A813-8B9815EA677A_1_2">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_18">-4422000</us-gaap:NetIncomeLoss>
  <us-gaap:Revenues contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_0">130000</us-gaap:Revenues>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_8">-4668000</us-gaap:OperatingIncomeLoss>
  <us-gaap:GrossProfit contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_2">72000</us-gaap:GrossProfit>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_10">1000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_15">246000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_16">-4422000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_13">232000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_14">2321000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_7">4740000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_4">94000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_CE6D1025-AB09-4084-A813-8B9815EA677A_1_0">89000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_5">4643000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_6">3000</us-gaap:DepreciationAndAmortization>
  <us-gaap:CostOfRevenue contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_1">58000</us-gaap:CostOfRevenue>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_1_12">2334000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1637754" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60EADD80-ABFF-40AB-9C13-AB0DD87F361A_1001_0">-1000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1732474" unitRef="iso4217_USD" decimals="-5" id="id_9160902_70C83B15-F7C0-4D14-8F49-4D169AEA98F4_1001_0">-300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1732774" unitRef="iso4217_USD" decimals="-3" id="id_9160902_869A1765-D840-4EA2-8C93-07661187CDB7_1001_400000">-33000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1802496" unitRef="iso4217_USD" decimals="-3" id="id_9160902_5D88D9BA-E3CD-4799-890D-94F2D2BD63B5_1001_0">-60000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1824912" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60DCB710-7769-4813-9F68-1337611475B5_1001_1">200000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1920444" unitRef="iso4217_USD" decimals="-3" id="id_9160902_520B2E6E-3AD8-41FE-8B06-98CCE3472547_1001_1">15000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1921945" unitRef="iso4217_USD" decimals="-5" id="id_9160902_6EDA1CFC-F930-43C6-A1C1-AEC2D7DEFA8D_1001_0">900000</emis:FairValueOfWarrantsDecreased>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1936828" unitRef="iso4217_USD" decimals="-5" id="id_9160902_5FEBBCEF-C0E2-4062-B1A3-60C51857BE2A_1001_0">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_19">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="shares" decimals="0" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_20">60687478</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_18">-14373000</us-gaap:NetIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_8">-2120000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_10">-3000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_15">-12253000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_16">-14373000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_13">148000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
  <us-gaap:InterestExpenseRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_14">1813000</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:OperatingExpenses contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_7">2120000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_4">229000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_5">1887000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:DepreciationAndAmortization contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_6">4000</us-gaap:DepreciationAndAmortization>
  <emis:DerivativeGainLossOnDerivativeNetRelatedParty contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_9160902_113DD423-D06D-4969-97B1-9AEC18A63372_2_12">-10585000</emis:DerivativeGainLossOnDerivativeNetRelatedParty>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1637754" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60EADD80-ABFF-40AB-9C13-AB0DD87F361A_1003_0">500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1732474" unitRef="iso4217_USD" decimals="-5" id="id_9160902_70C83B15-F7C0-4D14-8F49-4D169AEA98F4_1003_0">8100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1732774" unitRef="iso4217_USD" decimals="-5" id="id_9160902_869A1765-D840-4EA2-8C93-07661187CDB7_1003_600001">900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1802496" unitRef="iso4217_USD" decimals="-3" id="id_9160902_5D88D9BA-E3CD-4799-890D-94F2D2BD63B5_1003_0">-2000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1824912" unitRef="iso4217_USD" decimals="-5" id="id_9160902_60DCB710-7769-4813-9F68-1337611475B5_1003_1">100000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsDecreased contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1920444" unitRef="iso4217_USD" decimals="-3" id="id_9160902_520B2E6E-3AD8-41FE-8B06-98CCE3472547_1003_1">43000</emis:FairValueOfWarrantsDecreased>
  <emis:FairValueOfWarrantsIncreased contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1921945" unitRef="iso4217_USD" decimals="-5" id="id_9160902_6EDA1CFC-F930-43C6-A1C1-AEC2D7DEFA8D_1003_1">500000</emis:FairValueOfWarrantsIncreased>
  <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1936828" unitRef="iso4217_USD" decimals="-5" id="id_9160902_5FEBBCEF-C0E2-4062-B1A3-60C51857BE2A_1003_0">600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
  <us-gaap:ProfessionalFees contextRef="eol_PE5372----1510-Q0007_STD_92_20140930_0_1643325x1691094_1643986x1636114" unitRef="iso4217_USD" decimals="-3" id="id_9160902_1412DF57-3F92-42F9-8C3A-7477A677D2F6_1001_0">225000</us-gaap:ProfessionalFees>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1643325x1691094_1643986x1636114">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:MhrPromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1921945">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1824912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1802496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0_1636324x1637754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_92_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1921945">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1824912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1802496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0_1636324x1637754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_91_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2015-07-02</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1921945">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1802496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1737996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0_1636324x1637754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_365_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x2002476_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:Glp1LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1643986x1643540">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997525">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">emis:DevelopmentOfAdditionalNonExclusivelyLicensedMoleculeClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997524">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">emis:DevelopmentAndSalesOfAdditionalExclusivelyLicensedMoleculeClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">emis:DevelopmentAndSalesOfExclusivelyLicensedMoleculeClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766_1639304x1633605_1643986x1997522">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">emis:DevelopmentOfNonExclusivelyLicensedMoleculeClassMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_31_20151031_0_1634968x1997496_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-01</startDate>
      <endDate>2015-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643986x1636114">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643973x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1643325x1691094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:MhrPromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1639304x1643741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1639304x1633605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1921945">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1824912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1802496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1737996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1636324x1637754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1976750">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">emis:NonExecutiveEmployeesAndConsultantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1846485">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">emis:OutsideDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1639460">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1637088">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1635457x1634496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:PresidentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1634505x1638371_1639304x1643741">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1634505x1638371_1639304x1633605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1634505x1633425">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1633944x1965447_1635457x1641124_1640267x1946637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">emis:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">emis:OptionTwoPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1633944x1965446_1635457x1641124_1640267x1946637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">emis:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">emis:OptionOnePricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0_1633944x1965446_1635457x1637088_1640267x1946637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">emis:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">emis:OptionOnePricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefExecutiveOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1921945">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1824912">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1802496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0_1636324x1637754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_273_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20151026_0_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-26</startDate>
      <endDate>2015-10-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20151026_0_1634968x2002476_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:Glp1LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-26</startDate>
      <endDate>2015-10-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20151026_0_1634968x1997496_1636141x1633766">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">emis:ExpansionLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-10-26</startDate>
      <endDate>2015-10-26</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20150930_0_1643325x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20150930_0_1643325x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-09-30</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20150303_0_1635457x1641124">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-03-03</startDate>
      <endDate>2015-03-03</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20150520_0_1635457x1641124">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-05-20</startDate>
      <endDate>2015-05-20</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20150520_0_1633944x1965446_1635457x1641124_1640267x1946637">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">emis:BlackScholesOptionPricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">emis:OptionOnePricingModelMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:ChiefFinancialOfficerMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-05-20</startDate>
      <endDate>2015-05-20</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_1_20140820_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <startDate>2014-08-20</startDate>
      <endDate>2014-08-20</endDate>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150106_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-06</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643973x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1870932">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:AmendedAndRestatedReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1823297">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:AmendedAndRestatedBridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1755761">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:SecondAmendedAndRestatedBridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1755068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:AmendedAndRestatedConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1643325x1665212">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:SecondAmendedAndRestatedReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1921945">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1860618">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedAugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1830936">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1821050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1802496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1783900">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JuneTwoThousandAndTenMhrWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1774308">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenMhrWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1737996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1733630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndNineWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1701830">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenMhrWaiverWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1636324x1637754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634760x1637150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634760x1634767">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634505x1638371">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0_1634505x1633425">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20110112_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-01-12</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643986x1636114">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:RoyaltyArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643973x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1870932">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:AmendedAndRestatedReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1823297">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:AmendedAndRestatedBridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1755761">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:SecondAmendedAndRestatedBridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1755068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:AmendedAndRestatedConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1643325x1665212">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:SecondAmendedAndRestatedReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1640593x1746595_1643325x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">emis:SecondAmendedAndRestatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1640593x1746595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">emis:SecondAmendedAndRestatedMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1921945">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenRestructuringWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1920444">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1860618">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedAugustTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1830936">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJulyTwoThousandAndElevenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1821050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:TwoThousandAndThirteenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1802496">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AmendedAndRestatedJuneTwoThousandAndTenWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1783900">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JuneTwoThousandAndTenMhrWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1774308">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenMhrWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1737996">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:JulyTwoThousandAndElevenInvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1733630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndNineWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ReimbursementNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1732474">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:ConvertibleNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1701830">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">emis:AugustTwoThousandAndTenMhrWaiverWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1636324x1637754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634760x1637150">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634760x1634767">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634505x1638371">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0_1634505x1633425">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetsHeldUnderCapitalLeasesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2015-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20121017_0_1643325x1936828">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:BridgeNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-10-17</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20050926_0_1643325x1691094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:MhrPromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2005-09-26</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20050926_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2005-09-26</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150701_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-07-01</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150701_0_1639304x1633605">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-07-01</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20100608_0_1643325x1691094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:MhrPromissoryNotesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-06-08</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20150406_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-04-06</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20151116_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2015-11-16</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20141104_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-11-04</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20140820_0_1643325x1741680">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">emis:LoanAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-08-20</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20140820_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2014-08-20</instant>
    </period>
  </context>
  <context id="eol_PE5372----1510-Q0007_STD_0_20060516_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0000805326</identifier>
    </entity>
    <period>
      <instant>2006-05-16</instant>
    </period>
  </context>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Borrowing">
    <measure>emis:Borrowing</measure>
  </unit>
</xbrl>